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Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the Swedish Work Environment
Authority (SWEA). In most cases a scientific basis is written on request from the SWEA.
The Criteria Group shall not propose a numerical occupational exposure limit value but,
as far as possible, give a dose-response/dose-effect relationship and the critical effect of
occupational exposure.
In searching of the literature several databases are used, such as Arbline, Chemical
abstracts, Cheminfo, Medline (Pubmed), Nioshtic, RTECS, Toxline. Also information in
existing criteria documents is used, e.g. documents from WHO, EU, US NIOSH, the
Dutch Expert Committee for Occupational Standards (DECOS) and the Nordic Expert
Group (NEG). In some cases criteria documents are produced within the Criteria Group,
often in collaboration with DECOS or US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to the SWEA.
This is the 27th volume that is published and it contains consensus reports approved by
the Criteria Group during the period October 2005 through June 2006. These and
previously published consensus reports are listed in the Appendix (p 58).
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1Consensus Report for Ammonia
October 24, 2005
This Report is based primarily on a criteria document compiled by the Nordic
Expert Group for Criteria Documentation of Health Risks from Chemicals (28).
Chemical and physical data
CAS No.: 7664-41-7
Formula: NH3
Molecular weight: 17.03
Melting point: 77.7 °C
Boiling point: - 33.4 °C
Vapor pressure: 857 kPa (20 °C)
   (28% aqueous solution:  59 kPa)
Solubility in water: 529 g/l (20 °C)
PKa 9.15 (37 °C)
Conversion factors: 1 mg/m3 = 1.4 ppm
1 ppm = 0.7 mg/m3 (25 °C)
Ammonia at room temperature is a colorless gas with a penetrating odor. The
reported odor threshold is 5 to 6 ppm (28). Ammonia gas can be condensed by
cooling under high pressure, and then stored and transported as liquid ammonia
(anhydrous ammonia) (23). Ammonia dissolves quite readily in water and often
occurs as an aqueous solution, usually about 28 to 30%. Solutions that are more
concentrated than about 25-30% tend to release gaseous ammonia at normal
temperatures. Ammonia in water yields ammonium hydroxide and the aqueous
solution is basic (28, 29, 33).
In Swedish industry, ammonia is used mostly as an intermediate in various
processes. It is also used in production of commercial fertilizer, as a pH regulator,
as a flux, in cleaners, in surface treatments, as a refrigerant and in paints (28, 29).
Some liquid ammonia (anhydrous ammonia) is also sold and used as commercial
fertilizer (37). Exposure to ammonia can also occur around farm animals, and
ammonia is part of the natural nitrogen cycle (28).
Uptake, biotransformation, excretion
Ammonia occurs naturally in the body. It is created and used in protein
metabolism and is a normal part of all tissues (24, 28). Nearly all ammonia
formed in the intestine (mostly from food) is absorbed. The content of ammonia in
arterial blood from healthy persons is usually around 45 μmol/l, but with physical
2work the muscles produce ammonia and the blood level can rise. Elevated blood
levels of ammonia can also result from disturbances of liver and kidney function.
Under normal physiological conditions >98% is in the form of ammonium ions
(14, 16, 28, 29).
Occupational exposure to ammonia occurs primarily via inhalation (28).
Ammonia is hygroscopic, and is usually absorbed in the upper respiratory
passages. With high humidity and aerosol formation, however, uptake can occur
further down in the lungs (28). Experiments with volunteers showed that with
exposure to 56 – 500 ppm ammonia for up to 2 minutes, retention was about 92%
and independent of the exposure level (25). With exposure to 500 ppm for 15 or
30 minutes, retention at equilibrium (after 10 to 27 minutes) was reported to be on
average 23% (36). A calculation made by WHO indicates that exposure to 25 ppm
ammonia would raise the blood level of ammonia by only 0.09 mg/l (5 μmol/l),
assuming 30% retention and absorption. This level is about 10% above the fasting
level in arterial blood (24, 42). Concentrations that damage the skin probably
result in skin absorption, but there are no quantitative data (28).
Absorption and distribution of ammonia are highly dependent on pH. Non-
ionized ammonia, which is more readily soluble in fat, diffuses freely in the
cells, whereas the ammonium ion penetrates the cell membrane to a lesser extent.
Ammonia is metabolized primarily in the liver, where it is rapidly transformed to
urea with the aid of several different enzymes. The urea can be excreted in urine.
The other major metabolism pathway in the liver leads to formation of glutamine
via the enzyme glutamine synthetase. Glutamine can also be synthetized in other
organs, and this is the primary detoxification mechanism for ammonia in tissues
such as the brain. However, glutamine synthetase in the brain can not be induced
with hyperammonemia; thus in such circumstances ammonia concentrations can
rise considerably (16, 28). Glutamine is split into ammonia and glutamate by the
enzyme glutaminase. In the kidneys this can lead to excretion as ammonium ions
in urine, which is relevant to the acid-base balance in the body (28, 29). A little
bit of ammonia is also eliminated in exhaled air, probably due to synthesis of
ammonia from urea in saliva (28).
Toxic effects
Ammonia is irritating and caustic to skin and mucous membranes. The local
effects are due mostly to the strong alkalinity of the substance. Since ammonia
dissolves readily in water, it affects primarily the mucous membranes of eyes and
upper respiratory passages, but at higher air concentrations the bronchi and lungs
can also be affected. Ammonia can also cause sensory irritation of airways via the
trigeminus nerve (6, 9, 28, 33, 39).
Human data
About 30 minutes of exposure to 2500 – 4500 ppm ammonia has been reported
to be potentially lethal (3, 6, 28). The most common cause of death after acute
3exposure to high concentrations of ammonia (gas or anhydrous liquid) is laryn-
geal or pulmonary edema (23). High, brief exposures cause immediate damage,
with inflammation in respiratory passages (e.g. laryngitis, tracheobronchitis,
pneumonia), and can also have chronic effects in the form of reduced lung
function (15, 28). High, acute exposure to ammonia can cause irritant-induced
asthma (reactive airways dysfunction syndrome, or RADS). In addition, exposure
to ammonia can exacerbate pre-existing asthma (6, 7, 12). RADS was diagnosed
in two painters exposed to ammonia and other substances for 12 hours while
spray-painting an apartment. The workers used only paper masks for protection,
and ventilation was extremely poor. Symptoms (general weakness, nausea,
coughing, breathlessness, chest tightness, wheezing, paint taste in the mouth)
began to show up after 12 hours of exposure. Both subjects had lower lung
function and elevated bronchial reactivity to metacholine, and were hospitalized
for two weeks (preliminary diagnosis acute chemical bronchitis). Four months
after the incident the painters still had symptoms in the form of coughing,
wheezing, breathlessness with exertion, and increased sensitivity to non-specific
stimuli such as cold or smoke (11).
In an older study, 7 volunteers were exposed via breathing masks (covering
nose and mouth) to 500 ppm anhydrous ammonia for 30 minutes. Reduced
sensitivity in the skin covered by the mask and irritation of nose and throat, but no
coughing, was reported. Only two people managed to breathe through their noses
during the entire exposure. In previous experiments with higher concentrations
(1000 ppm) the exposure was reported to result in immediate coughing (36).
Sixteen subjects were exposed to 50, 80, 110 or 140 ppm ammonia for 2 hours:
no noteworthy effects were reported on vital capacity, FEV1 or FIV1 (reductions
≤10%) at any exposure level. There were concentration-dependent increases in
subjective estimates of eye irritation, nasal irritation and throat irritation, as well
as coughing, at 50 – 110 ppm, at 50 ppm generally regarded as slight (“just
perceptible” to “distinctly perceptible”). Eight of the subjects described 140 ppm
as strongly irritating and intolerable for 2 hours (43). In another study, 10 minutes
of ammonia exposure was reported to be moderately irritating by 4 of 6 subjects
at 50 ppm, and at 30 ppm irritation of eyes and nose was reported to be none or
barely noticeable (30). In one report (Keplinger et al. 1973, cited in Reference
39), nasal dryness was reported with 5 minutes at exposure to 32 ppm (1 subject)
and 50 ppm (2 subjects), and irritation of eyes, nose and throat was reported at
72 ppm. The concentrations are approximate (not measured directly). A recently
published study reports no significant changes in lung function (FEV1, diffusion
capacity) or bronchial hyperreactivity (metacholine provocation) when 6 healthy
persons and 8 persons with mild asthma were exposed to 16 – 25 ppm ammonia
for 30 minutes (35).
In a German study (21), 43 persons (10 of them regularly exposed to ammonia
at work) were exposed for five days to increasing concentrations of ammonia.
They were exposed for 4 hours/day to 0 ppm on day one, 10 ppm on day 2, 20
ppm on day 3, 20 ppm plus 40 ppm for 2 x 30 minutes on day 4, and 50 ppm on
day 5. No significant increase of inflammatory markers was found in nasal lavage
4and there were no significant changes in measurement of nasal airway resistance,
tear flow, bronchial reactivity or lung function. No effects on cognitive function
were observed. However, increasing discomfort with increasing ammonia
concentration was seen when assessing acute and irritative effects together (SPES
questionnaire), intensity of irritation (eyes, nose), and respiratory symptoms (chest
tightness, coughing, breathlessness). In the subjects accustomed to exposure, a
significant increase of irritation symptoms was reported only at 50 ppm and there
was no significant increase of respiratory symptoms at any exposure level. In
persons unaccustomed to exposure, both irritation symptoms and respiratory
symptoms increased significantly with increasing exposure, but the exposure
levels at which the increases became significant (besides 50 ppm) is not clear. The
rankings of irritation symptoms and of acute and irritative discomfort together
were indicative of slight to extremely slight discomfort at 10 – 20 ppm. The
rankings at 50 ppm showed very slight discomfort as a group average, although
some individuals reported more noticeable discomfort at this concentration.
Somewhat reddened conjunctiva were observed at 50 ppm in 3 of the 33 subjects
unaccustomed to exposure. This group described the odor as unpleasant at 10 ppm
and as fairly strong to strong at 50 ppm (21).
In a Swedish study, 12 healthy subjects were exposed to 0, 5 or 25 ppm
ammonia in an exposure chamber for 3 hours (38). The exposure yielded no
indications of inflammation in upper respiratory passages (nasal lavage), effects
on lung function or increased bronchial reactivity to metacholine, although dose-
dependent increases in subjective estimates of various symptoms were seen on a
rating scale (VAS, Visual Analogue Scale). The increases were significant for eye
irritation (p<0.01), dizziness (p<0.05), and feeling of intoxication (p<0.05) after
the 5 ppm exposure, although the assessments made during the exposure were low
(for eye irritation “hardly at all” on the scale). At 25 ppm there were significant
increases in estimates of all listed irritation and CNS-related symptoms, and no
indications of adaptation were seen. Average estimates during the exposure were
still quite low, however: irritation in eyes, nose, and throat/airways, breathing
difficulty and nausea got verbal rankings in the area “somewhat” on the VAS
scale. For dizziness, headache and feeling of intoxication the estimates were
even lower (38).
In a poorly reported study (17), 6 subjects were exposed on different schedules
to 25, 50 or 100 ppm ammonia for 2 to 6 hours/day, 5 days/week for up to 6
weeks. Mild irritation of eyes, nose and throat was reportedly observed in
subsequent medical examinations, but tolerance development was suggested
and the subjects experienced no discomfort after the first week. No clear dose-
effect correlation was seen (17).
In a study of 58 workers exposed to ammonia in the production of sodium
carbonate, tests of lung function showed no differences from controls. Nor was
there any observed difference in prevalence of symptoms involving respiratory
passages, eyes or skin, although the exposed workers reported that some
symptoms (including coughing, eye irritation) were more severe with exposure.
There was no discernible difference between the groups in tests of odor threshold
5during the workweek. Average ammonia exposure for the entire group was 9.2
ppm (time-weighted average, 8.4 hours). Exposure levels were reported to be
below 50 ppm and in most cases below 25 ppm (22).
In a study of 161 workers in two fertilizer factories and 355 unexposed
persons, a questionnaire indicated significantly higher relative risks of respiratory
symptoms (coughing, mucus, wheezing, breathlessness) in factory A, but not in
factory B. In factory A the air concentration of ammonia (8-hour) was 2 – 130.4
mg/m3 (2.8 – 183 ppm) and in factory B 0.02 – 7 mg/m3 (0.03 – 9.8 ppm). In
factory A the geometric means were below 18 mg/m3 (25 ppm) except in the
packing area (18.6 mg/m3) and the storage area for urea (115.1 mg/m3) (stationary
samplers, 8-hour samples). The urea storage area was not to be entered without
“full protective clothing”. According to the authors there were no other substances
at the workplace besides ammonia that could affect respiratory passages. The
production processes had not been changed since production began, and the
measured ammonia levels were therefore considered representative. The exposed
workers had been employed for an average of 51.8 months. When they were
divided into exposure groups, significantly higher relative risks for coughing,
mucus, wheezing, breathlessness and diagnosed asthma were seen for those
exposed to average ammonia levels above 25 ppm, but for wheezing alone at
average levels at or below 25 ppm. A calculation based on cumulative ammonia
concentration yielded significant increases of respiratory symptoms as well as
asthma and chronic bronchitis at levels >50 mg/m3-year (>70 ppm-year), but for
wheezing alone at levels ≤50 mg/m3-year (≤70 ppm-year). It is also reported that
most of the asthma cases worked in locations with “high” ammonia concentrations
(5).
In a later study, the same authors report data on lung function for 73 exposed
workers and 348 controls (probably from the above population). Somewhat lower
lung function (FEV1 and FVC in % of expected values) was noted in highly
exposed workers when compared to a group with lower exposure, but not when
compared to the unexposed group. FEV1 in % of expected value, and FEV1/FVC
in % of expected value, were significantly lower for exposed workers with
symptoms than for those without symptoms. FEV1 in % of expected value was
also significantly lower for the group of exposed non-smokers with symptoms.
The ammonia concentrations (4-hour samples) ranged from 2 to 130.4 mg/m3 (77
exposed workers). The geometric means were 5.5 mg/m3 (range 2 – 8.1 mg/m3)
and 5.0 mg/m3 (range 2.6 – 15 mg/m3) in two departments, 18.6 mg/m3 (range
10 – 27.1 mg/m3) in the packing area and 115.1 mg/m3 (range 90 – 130.4 mg/m3)
in the urea storage area (2).
Coughing, breathlessness and wheezing were reported in a person who had
been using a silver polish containing ammonia in a small, poorly ventilated room.
He had no previous history of asthma, and began to develop symptoms after 5
months of employment. He reported a strong odor of ammonia during his work,
and measurements in the breathing zone showed 8 – 15 ppm. In addition to
ammonia, the polish contained isopropyl alcohol, clay, fatty acid and water. He
had no symptoms when he used a brass polish that produced an air concentration
6of <1 ppm ammonia (27). In a controlled exposure, he developed rhinitis, watery
eyes, and coughing after about 15 minutes of using the symptom-producing
polish. Rhonchus was noted in both lungs. PEFR dropped by 42%, rose again
after treatment with medicine to reduce asthma symptoms, and six hours later
again dropped by 18%. In another controlled exposure, he was exposed to 12 ppm
ammonia and within two minutes had an asthma attack with rhonchus in both
lungs; PEFR fell by about 55%. Histamine provocation showed non-specific
bronchial hyperreactivity (27). No delayed reaction was reported after the
exposure to 12 ppm ammonia. A causal connection between exposure to low
concentrations of ammonia and induction of asthma can not be established on
the basis of this study.
Correlations between exposure to air pollutants in barns, stables and henhouses
and increased occurrence of respiratory symptoms, bronchial inflammation and
reduced lung function have been reported in some studies. The extent to which
ammonia contributed to these effects is not clear, however, since the workers were
also exposed to other substances including organic dust and endotoxins (26, 28,
34).
There are numerous reported cases of severe eye damage, including glaucoma
and cataracts, attributed to a spray or splash of ammonia either in anhydrous form
or as a concentrated solution. When one drop of 9% ammonium hydroxide
solution was inadvertently dropped into one eye, most of the corneal epithelium
was destroyed despite flushing the eye with water within 10 seconds. The eye
healed in 3 to 4 days with no lasting damage (20). Severe skin damage has also
been reported, especially in connection with using anhydrous ammonia as
fertilizer in agriculture (3, 45).
Animal data
The LC50 for laboratory rodents is reported to be about 10,000 to 40,000 ppm for
10 minutes of exposure and 4,230 – 16,600 ppm for 1 hour of exposure (28). No
acute effects (hypo- or hyperactivity, spasms) were observed in rats exposed for 2
hours to 121 ppm (Alpatov & Mikhailov 1963, cited in Reference 24). The RD50
(the concentration that produces a 50% reduction in respiratory rate), a measure of
respiratory irritation, has been reported to be about 260 – 300 ppm for mice (15 –
30 minutes) (8, 28, 46).
No indications of toxicity were reported in a study (13) in which rats, rabbits,
guinea pigs, dogs and monkeys were exposed to 56 ppm for 114 days, and rats
were exposed to 178 ppm for 90 days. No noteworthy changes were observed,
either in histopathological examinations (including lungs, liver, kidneys, heart,
spleen) or in various biochemical and hematological parameters. In a sketchily
described study, no toxic effects were observed in rats after two months of
exposure to 57 ppm; however, histological changes (indications of inflammation)
were observed in lungs, but not in other organs, at 143 ppm (Alpatov & Mikhailov
1963, cited in Reference 24). In some other rat studies as well, constant exposure
to 150 – 200 ppm for a few weeks up to a few months has been reported to result
7in histopathological changes in airways (e.g. loss of cilia, hyperplasia) (10, 19). In
an older study in which guinea pigs were exposed to about 170 ppm (140 – 200
ppm) ammonia 6 hours/day, 5 days/week for up to 18 weeks, no significant
changes were observed in microscopic examinations of animals killed after 6 and
12 weeks (44). The animals that were killed after 18 weeks, however, had slight
changes in spleen, kidneys, adrenals and liver. The most pronounced changes
were in the spleen (including congestion, hemosiderin). An incompletely de-
scribed experiment, in which mice were exposed to vapor from a 12% ammonia
solution 15 minutes/day, 6 days/week for 4 to 8 weeks, reports effects on enzymes
(succinate dehydrogenase, acidic and alkalic phosphatases, non-specific esterases)
and histological changes in respiratory passages (loss of cilia, epithelial hyper-
plasia, squamous cell metaplasia, dysplasia in nasal epithelium etc.) that became
more pronounced with increasing length of exposure (18).
Rats were exposed to 25 – 250 ppm ammonia for a week and then given nasal
inoculations of Mycoplasma pulmonis, after which the exposures were continued
for a further 4 to 6 weeks. Indications of more severe mycoplasma infections were
seen at all concentrations. The prevalence of pneumonitis also showed a tendency
to increase with concentration (10). In another study, cell-mediated immune
response to provocation with a tuberculin derivative was reduced in guinea pigs
that were exposed to 90 ppm ammonia for 3 weeks (40).
Genotoxicity
There are few studies. Mutagenic effects have been reported in a few studies at
toxic levels of ammonia (gas, ion form), but no conclusions can be drawn from
these data (28).
Carcinogenicity
Mice were exposed to vapor from a 12% ammonia solution 15 minutes/day, 6
days/week: histological changes, increasing with exposure, were observed in
airways. Ten exposed animals and 5 controls were killed each week in weeks
4 – 8. In week 6, epithelial hyperplasia was seen and 4 animals had flecks of
squamous cell metaplasia. In week 7, 3 animals had dysplasia in nasal epithelium
and one animal had carcinoma in one nostril. Changes observed in week 8 in-
cluded adenocarcinoma in the nasal mucosa of one animal (18). The study is
not fully reported; there are no weight curves or other information on effects
on the mice. The latency time is remarkably short.
No carcinogenic effects were observed in mice after lifelong administration of
0.1, 0.2 or 0.3% ammonium hydroxide in drinking water (41). Other studies with
oral administration of ammonia suggest that the ammonium ion can contribute to
cancer development by functioning as a promoter (28).
8Effects on reproduction
No toxicity studies of effects on human reproduction and no inhalation studies
of effects on animal reproduction were found (28). Rats exposed to ammonia
prenatally and in breast milk via oral administration of high doses of ammonium
acetate to their dams (20% w/w in feed, equivalent to about 4 g ammonium ion/kg
b.w./day) showed inhibited growth, poor function of N-methyl-D-aspartate
receptors in the CNS and effects on learning (1, 32). No mention is made of toxic
effects on the dams, but toxic effects can be expected since growth inhibition was
seen in adult male rats exposed in the same way in another study (4). In the study
by Aguilar et al. (1) that showed effects on learning, the rats were exposed (via
feed) after weaning also, and there was no adequate control group. For these
reasons no conclusions can be drawn from these studies regarding toxic effects
of ammonia on reproduction.
Dose-effect / dose-response relationships
A significant increase of eye irritation (p<0.01) was reported by subjects in a
study in which they were exposed to 5 ppm for 3 hours, although the assessments
they made during the exposure were low: equivalent to “hardly at all” (38). In
this study, therefore, the NOAEL was concluded to be 5 ppm. At 25 ppm the
assessments of all the discomfort and CNS effects on the questionnaire were
significantly higher, and no indication of adaptation was observed. The average
estimate during the exposure for symptoms of irritation in eyes, nose and
throat/respiratory passages, breathing difficulty and nausea was in the neigh-
borhood of “somewhat”. For dizziness, headache and feelings of intoxication,
the estimates were lower (38). In another study with short-term exposure to 10 –
50 ppm, subjects reported increasing discomfort with increasing ammonia
concentration, for acute and irritative discomfort together, for symptoms of
irritation in eyes and nose and for respiratory symptoms (chest tightness,
coughing, breathlessness). At 50 ppm, persons accustomed to exposure reported
significantly more pronounced irritation symptoms in eyes and nose, compared
to zero exposure, but there was no significant increase of respiratory symptoms
at any exposure level. Persons unaccustomed to exposure are more sensitive, but
it is not clear at what exposure levels the increases of irritation and respiratory
symptoms became significant. No indications of inflammation in upper airways,
effects on lung function or increased bronchial reactivity were reported in either
of these studies (21, 38). Some subjects reported that 140 ppm was extremely
irritating and intolerable for 2 hours (43).
Few reliable measures of occupational exposure to ammonia have been
reported. There is also the problem of mixed exposures, which makes it difficult
to sort out the effects of ammonia alone. In a study of workers exposed to air
concentrations of ammonia averaging 9.2 ppm around production of sodium
carbonate, lung function, prevalence of reported eye, nose or respiratory
symptoms, and sense of smell were no different from controls. The exposed
9persons reported that some symptoms (including coughing and eye irritation)
were worse with exposure (22). Nor was there any significant increase in relative
risk for respiratory symptoms (coughing, mucus, wheezing, breathlessness) in the
workers in another study, who were exposed to air concentrations (8-hour meas-
urements) of 0.03 – 9.8 ppm (5). A significantly higher relative risk of wheezing
was reported at an average ammonia level of ≤25 ppm, and for respiratory symp-
toms and asthma at average levels of >25 ppm (5). In calculating the cumulative
ammonia concentration, a significant increase of respiratory symptoms, as well as
of asthma and chronic bronchitis, was noted at levels >50 mg/m3-year (>70 ppm-
year), but only wheezing at levels ≤50 mg/m3-year (≤70 ppm-year). Smoking may
have influenced the results, but the ammonia concentration was the only signifi-
cant variable for asthma and wheezing/breathlessness (5).
Exacerbation of asthma that is not caused primarily by factors in the work
environment, as well as the appearance of asthma, have been reported in several
studies with high, acute exposure to ammonia (6, 7, 11, 12). However, no
significant changes in results of lung function tests and tests of bronchial
hyperreactivity were reported when persons with mild asthma were exposed to
16 – 25 ppm ammonia for 30 minutes (35). In a controlled study with exposure
to 12 ppm ammonia, ammonia was identified as the etiological agent for asthma
in a person who had been occupationally exposed to 8 – 15 ppm ammonia for 5
months while using silver polish (27). No other reports have been found of asthma
with exposure to ammonia alone at such low air concentrations, and on the basis
of present knowledge it is impossible to say whether low exposure to ammonia
without previous high exposure can cause asthma.
Dose-effect relationships in people exposed to ammonia by inhalation are
summarized in Table 1.
Dose-effect relationships observed in inhalation experiments with animals
are summarized in Table 2.
Conclusions
The critical effect of exposure to ammonia is irritation of eyes and respiratory
passages. Slight symptoms of irritation have been reported by experimentally
exposed persons with short-term exposure to air concentrations around 20 – 25
ppm. Some eye discomfort has been reported at lower concentrations. One study
of ammonia-exposed workers suggests that wheezing can appear at air concen-
trations below 25 ppm.
High, acute exposures can cause laryngeal and pulmonary edema, sometimes
with fatal outcome. Appearance of asthma symptoms in direct connection to
exposure to high concentrations of ammonia has also been reported. Ammonia
can also intensify asthma caused by factors outside the work environment.
Ammonia in anhydrous form and concentrated ammonia solutions can cause
severe burns if they come into direct contact with skin or mucous membranes.
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Table 1. Dose-effect relationships observed in humans exposed to ammonia by inhalation.
Concentration Duration Number Effects Ref.
mg/m3 ppm exposed
3.5 5 180 min 12 No indication of inflammation in upper
airways, no increase in bronchial reactivity, no
effect on lung function.
Significantly higher subjective estimates of eye
irritation (p<0.01), dizziness (p<0.05) and
feeling of intoxication (p<0.05), although
estimates during the exposure were low.
Subjective estimate of eye irritation was
“hardly at all”.
38
6.4 9.21 occupational
exposure
58 No differences from controls in lung function
(FVC, FEV1, FEV1/FVC, FEF50, FEF75) or
prevalence of reported symptoms involving
respiratory system, eyes and skin. No effect on
sense of smell during the work week.
22
7 10 240 min 43 No indications of inflammation in upper
airways, no increase in bronchial reactivity, no
effects on lung function.
Unaccustomed persons reported increased
irritation (eyes, nose) and respiratory
symptoms, but the significance is unclear.
Some discomfort from the odor.
21
11-18 16-25 30 min 6 healthy
subjects +
8 with
mild
asthma
No significant effect on FEV1, diffusion
capacity in lungs or bronchial hyperreactivity
with metacholine provocation in either group.
35
14 20 240 min 43 No indication of inflammation in upper
respiratory passages, no increase in bronchial
reactivity, no effects on lung function.
Unaccustomed persons: higher estimates of
irritation (eyes, nose) and respiratory
symptoms, but significance unclear. Odor
unpleasant.
21
≤18 ≤252 occupational
exposure
138 Higher relative risk of wheezing (RR 2.26;
95% CI: 1.32 – 3.88).
5
>18 >253 occupational
exposure
17 Higher relative risks for:
coughing (RR 3.48; 95% CI 1.84 – 6.57)
mucus (RR 3.75; 95% CI 1.97 – 7.11)
wheezing (RR 5.01; 95% CI 2.38 – 10.57)
breathlessness (RR 4.57; 95% CI 2.37 – 8.81)
asthma (RR 4.32; 95% CI 2.08 – 8.98)
5
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Table 1. Cont.
Concentration Duration Number Effects Ref.
mg/m3 ppm exposed
17.5 25 180 min 12 No indication of inflammation in upper
respiratory passages, no increase in bronchial
reactivity, no effects on lung function.
Significantly higher estimates of irritation and
CNS-related symptoms. Estimates during
exposure were “somewhat” for irritation of
eyes, nose and throat/airways; breathing
difficulty and nausea, and even lower for
dizziness, headache and feeling of intoxication.
38
21 30 10 min 5 No irritation (3/5) or barely noticeable
irritation (2/5) of eyes and nose.
30
14
+ 28
20
+ 40
240 min
+ 60 min
43 No indications of inflammation in upper
airways, no increase in bronchial reactivity, no
effects on lung function.
Unaccustomed persons: higher estimates of
irritation (eyes, nose) and respiratory
symptoms; significance unclear. Odor
unpleasant.
21
35 50 240 min 43 No indications of inflammation in upper
airways, no increase in bronchial reactivity, no
effects on lung function.
Unaccustomed persons: significantly higher
estimates of irritation (eyes, nose) and
respiratory symptoms; swelling/redness of
conjunctiva in 3/33. Odor unpleasant.
Accustomed persons: significantly higher
estimates of irritation (eyes, nose). Some
discomfort from odor.
21
35 50 10 min 6 Moderate irritation of eyes and nose in 4/6:
barely noticeable irritation in 1/6.
30
35 50 120 min 16 VC, FEV1 and FIV1 reduced by no more than
10%. Slight/relatively slight irritation of eyes,
nose and throat.
43
70 100 5-30 seconds 23 Duration-dependent increase of airway
resistance in nose, nasal irritation in 11/23.
31
77 110 120 min 16 VC, FEV1 and FIV1 reduced by ≤10%.
Irritation of eyes, nose, throat; coughing.
43
98 140 up to
120 min.
16 VC, FEV1 and FIV1 reduced ≤10%.
Intolerable for 8/16.
42
1
 Time-weighted average (TWA); personal monitors, average sampling time 8.4 hours (exposure
levels <50 ppm, in most cases <25 ppm).
2
 Geometric mean; stationary monitors, 8-hour shift.
3
 Geometric mean; stationary monitors, 8-hour shift (maximum exposure level 182 ppm)
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Table 2. Dose-effect relationships observed in animals experimentally exposed to ammonia
by inhalation.
Exposure
(ppm)
Exposure
time
Species Effects Ref.
25 7 days
+ 30-42 days
constant
rat More severe mycoplasma infections
after nasal inoculation with
Mycoplasma pulmonis.
10
56 114 days
constant
rat
rabbit
guinea pig
dog
monkey
No indications of toxicity, no
noteworthy histopathological changes.
13
57 2 months rat No toxic effects. Alpatov &
Mikhailov 1963,
cited in Ref. 24
90 3 weeks
constant
guinea pig Reduced cell-mediated immune
response
40
121 2 hours rat No acute effects (hypo- or
hyperactivity, spasms).
Alpatov &
Mikhailov 1963,
cited in Ref. 24
143 2 months rat Histological changes in lungs
(including small areas of interstitial
pneumonia), no changes in other
examined organs.
Alpatov &
Mikhailov 1963,
cited in Ref. 24
150 75 days
constant
rat Histological changes (including
hyperplasia) in olfactory and
respiratory epithelium in nasal cavity.
10
170 6 hours/day
5 days/week
up to 18 weeks
guinea pig After 18 weeks: relatively mild
histological changes in spleen,
kidneys, adrenals and liver.
44
178 90 days
constant
rat No indications of toxicity, no
noteworthy histological or
hematological changes, no
histochemical changes in liver.
13
200 4 – 12 days
constant
rat Histopathological changes in trachea,
including loss of cilia and hyperplasia.
19
257 15 min. mouse RD50 46
303 30 min. mouse RD50 8
367 90 days
constant
rat Slight irritation in 25% of animals. 13
658 90 days
constant
rat
rabbit
guinea pig
dog
monkey
Clear eye irritation in dogs and
rabbits, erosion of 1/4 - 1/2 of the
cornea in rabbits.
Histopathological changes in lungs,
kidneys, heart and liver.
13/15 rats died, 4/15 guinea pigs died.
13
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This Report is based primarily on a criteria document compiled by the Nordic
Expert Group (37). Like the criteria document, it is limited to the effects of
penicillins that are relevant in the context of occupational health, i.e. effects of
therapeutic use are not taken up. The most recent literature search was made in
April of 2005.
Chemical and physical data. Uses
Penicillins belong to the group of β-lactam antibiotics. Other antibiotics in this
group include cephalosporins, carbapenems and monobactams (59).
Penicillins can be divided into naturally occurring penicillins, penicillinase-
resistant penicillins, aminopenicillins, carboxypenicillins and ureidopenicillins
(see Table 1). They all have the same basic structure: 6-aminopenicillanic acid
(R1 and R2 = H in Figure 1), a linking of the amino acids L-cysteine and D-valine
forming a cyclic amide (β-lactam), which is attached to an imidazol ring. The
antibacterial properties of penicillins are attributed to their high affinity to
enzymes that synthesize the bacterial cell wall and to the reactivity resulting
from the flat arrangement of the ring system, with the high tension in the lactam
ring. Many penicillins are inactivated by enzymes, e.g. β-lactamases, which are
produced by some bacteria (27, 37, 65).
A large number of penicillins have been isolated and synthesized: differences in
the structure of the side chains R1 and R2 (Figure 1) give them different antibiotic
spectra, pharmacokinetics, and acid and β-lactamase stability. Examples of
penicillin structure and characteristics are shown in Table 1 (27, 65). As a rule,
penicillin salts of potassium, sodium and calcium are easily soluble in water,
whereas other counterions such as procaine and benzathine produce salts that
dissolve less readily (27).
Figure 1. A generalized diagram of the basic structure of penicillins.
S
N
O
NH
CO2
CH3
CH3
R1
R2
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Table 1. Examples of side-chain structure R1 (see Figure 1) and characteristics of some
penicillins (27, 65).
Name Synonym Structure1, R1 Characteristics2
Penicillin G3 benzylpenicillin G(+)
sensitive to acid and
 to β-lactamase
Penicillin V3 phenoxymethyl
penicillin
G(+)
acid-stable, sensitive
to β-lactamase
Ampicillin4 D-α-(-)-aminobenzyl
penicillin COCH
NH2
G(+) and G(–)
acid-stable, sensitive
to β-lactamase
Cloxacillin5 3-o-chlorophenyl-5-
methyl-4-isoxazolyl
penicillin
G(+)
acid-stable
β-lactamase resistant
Carbenicillin6 α-carboxybenzyl
penicillin
G(+) and G(–)
sensitive to acid and
to β-lactamase
Piperacillin7 4-ethyl-2,3-
dioxopiperazine-
carbonyl ampicillin
G(+) and G(–)
sensitive to acid and
to β-lactamase
1
 in all these penicillins R2 = H (see Figure 1), pKa = 2.6 – 2.8
2
 G(+) = effective primarily against gram-positive bacteria; G(-) = effective primarily against
  gram-negative bacteria
3
 naturally occurring penicillin
4
 aminopenicillin
5
 penicillinase-resistant penicillin
6
 carboxypenicillin
7
 ureidopenicillin/piperazine penicillin
Penicillins are solid powders with very low vapor pressure. Exposure to air-
borne penicillin is therefore usually due to aerosols from powders or solutions
containing penicillin (37).
A method for qualitative and quantitative determination of penicillin in work-
place air has been described (19). Qualitative (semi-quantitative) determination
of penicillin is based on the number of inhibition zones in a Petri dish containing
penicillin-sensitive bacteria in an agar gel that has been placed out in the work-
place. For quantitative determination of penicillin in air, air samples are taken on
a filter with the aid of an air pump. The amount of penicillin on the filter is then
determined by extraction and a bioassay that measures the inhibition of penicillin-
sensitive bacteria caused by the extract (19).
CH2 CO
O CH2 CO
O
N CH3
CO
Cl
CH
COOH
CO
COCO CHNHCH3 N NCH2
OO
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Some studies report air concentrations of penicillins around penicillin
production and handling of penicillin preparations (16, 23, 61), see below.
A NIOSH report (23) contains measures of total dust in a factory producing
17 different formulations from 4 penicillins. Total dust (measured by personal
monitors) in the breathing zone of production workers (weighing, granulating,
capsule filling, tablet pressing, powder filling) was 6.0 mg/m3. It was 0.3 mg/m3
for employees working with packaging and 0.5 mg/m3 for quality controllers. It
is not clear what proportion of the total dust was penicillin.
Shmunes et al. (61) reported ampicillin levels of 3.7 – 262 mg/m3 around
mixing, capsule filling and grinding and 0.005 – 0.789 mg/m3 around packaging,
and benzylpenicillin levels of 11 to 42,857 units/m3 around charging of reactors
(1 mg benzylpenicillin-potassium salt is equivalent to about 1500 units) in a
factory making synthetic penicillin.
Air contents of amoxicillin (Imacillin®) were measured around preparation of
an amoxicillin solution. Particle size in the aerosol was <3 μm and the average air
concentration of amoxicillin was 1.2 μg/m3 (range 0.69 – 2.95). Air concentra-
tions were measured by collection on a filter for 5 minutes and subsequent ex-
traction and analysis with traditional microbiological methods (16).
It is difficult to estimate the number of persons occupationally exposed to
penicillin in Sweden (37). Exposure occurs, or can be suspected to occur, for
several different types of workers, such as:
• People who work with production, processing and formulation of penicillins
and penicillin preparations in the pharmaceutical industry
• Pharmacists who prepare penicillin formulations
• Health care workers who administer penicillin preparations and care for
patients.
• Veterinarians, farmers and fish farmers who treat animals with penicillin.
• Laboratory workers who use penicillin in research or in standard analyses.
• Persons who handle waste containing penicillin
People take penicillin in the form of tablets, capsules, mixtures, drops, infusions
and injections, and animals are given tablets, mixtures, injections and preparations
for topical treatment of udder inflammations. In Sweden in 1999, 8.1 doses of
penicillin for human use were sold per 1000 inhabitants per day (2), equivalent to
about 27 tons per year if it is assumed that a one-day dose is about 1 gram. A large
portion of the Swedish population is therefore exposed to penicillin therapeuti-
cally. In veterinary medicine, 13.2 tons of benzylpenicillin (penicillin G) and 0.86
tons of ampicillin/amoxicillin were used in Sweden in 1993 (5).
A summary of penicillin preparations sold in Sweden in 2000 is given in Table
2. Structures, synonyms etc. are found in the criteria document (37).
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Table 2. Penicillin preparations registered for use in Sweden in 2000 (37).
Name   CAS
number
Formula Mol
weight
Procaine benzylpenicillin 54-35-3 C16H18N2O4S·C13H20N2O2 571
Ampicillin, sodium salt 69-52-3 C16H19N3O4S·Na 372
Benzylpenicillin, sodium salt 69-57-8 C16H18N2O4S·Na 357
Penicillin V, potassium salt 132-98-9 C16H18N2O5S·K 389
Cloxacillin, sodium salt 642-78-4 C19H18ClN3O5S·Na 459
Benethamine penicillin 751-84-8 C16H18N2O4S·C15H17N 546
Penicillin G benzanthine 1538-09-6 (C16H18N2O4S)2·C16H20N2 909
Penicillin G diethylaminoethyl
ester
3689-73-4 C22H31N3O4S 434
Procaine penicillin 6130-64-9 C16H18N2O4S·C13H20N2O2.H2O 589
Cloxacillin, sodium
monohydrate
7081-44-9 C19H17ClN3O5S·Na·H20 476
Dicloxacillin, sodium
monohydrate
13412-64-1 C19H16Cl2N3O5S·Na·H2O 510
Globacillin 17243-38-8 C16H17N5O4S 375
Pivampicillin hydroklorid 26309-95-5 C22H29N3O6S·HCl 500
Pivamdinocillin 32886-97-8 C21H33N3O5S 440
Selexid 32887-01-7 C15H23N3O3S 325
Pivmecillinam hydrochloride 32887-03-9 C21H33N3O5S·HCl 476
Ampicillin pivaloyl-
oxymethyl ester
33817-20-8 C22H29N3O6S 464
Bacampicillin hydrochloride 37661-08-8 C21H27N3O7S·HCl 502
Flucloxacillin 58486-36-5 (C19H16ClFN3O5S)2·Mg·8H2O 1 074
Amoxicillin trihydrate 61336-70-7 C16H19N3O5S·3H2O 419
In the 1995-2001 period there were 24 occupational injury reports citing
penicillin as a possible cause. During this same period there were 18 further
reports in which antibiotics or medicines were given as a possible cause. (The
Work Injury Information System [InformationsSystemet om Arbetsskador, ISA],
personal communication from Börje Bengtsson, Swedish Work Environment
Authority).
Uptake, distribution, metabolism, excretion
Since penicillin is skin-sensitizing it clearly can penetrate the skin, but no
quantitative data were found.
Only one study describing lung uptake of penicillin was found. Rats were
exposed for 5 minutes to an aerosol (mass median aerodynamic diameter
2.92±0.05 μm) consisting of benzylpenicillin (1 mM) dissolved in a phosphate
20
buffer, after which the lungs were examined at intervals for remaining benzyl-
penicillin. The half time for benzylpenicillin in the lungs was 20.5 minutes (6).
Absorption in the digestive tract of oral doses of penicillins designed for oral
use ranges from 30 to 90% (37). Maximum serum level is usually reached 1 to 2
hours after administration. Food intake can both retard and reduce absorption. If
penicillin is taken directly after a meal, for example, serum levels are 30 to 60%
lower than if the same dose had been taken on an empty stomach. Some peni-
cillins, such as the ureidopenicillins, are poorly absorbed in the digestive tract, and
others, such as benzylpenicillin, are broken down by gastric acid (27, 37, 65).
All penicillins are distributed well to most body tissues. There are a few
exceptions, most notably prostate, eyes and cerebrospinal fluid. Penicillin in blood
is reversibly bound to serum proteins in proportions ranging from 15% for amino-
penicillins to 97% for dicloxacillins. About 50% of benzylpenicillin is bound to
plasma proteins. Only the unbound fraction is biologically active (37, 65).
Most penicillin is excreted unchanged in urine, but a small portion is metabo-
lized. Up to ten percent of the metabolites form covalent bonds to lysine and
cysteine remnants in serum proteins, membrane proteins and microbial proteins.
Most (95%) of these bound metabolites are penicilloyl-protein conjugates called
“major determinants” because they are formed in the largest quantity. The rest of
the bound metabolites are referred to as “minor determinants”. These are less
well defined, but consist of metabolites from unmodified penicillin, penicilloate,
penilloate and possibly other breakdown products. Both the major determinants
and the minor determinants have been shown to be involved in life-threatening
allergic reactions to penicillin, the latter group possibly more often with anaphy-
lactic shock. The penicilloyl group bound to polylysine (penicilloyl polylysine,
PPL) is used in tests for penicillin allergy (9, 37, 59, 65, 66).
Penicillin and penicillin metabolites are rapidly excreted via the kidneys
(glomerular filtration and tubular secretion). The half time in serum is brief,
about 30 minutes for benzylpenicillin and 60 minutes for aminopenicillins.
A few penicillins, e.g. cloxacillins, nafcillin, oxacillin and ureidopenicillins,
are also excreted to some extent (20 to 30%) in bile (37, 65).
Toxic effects
Hypersensitivity reactions
Numerous articles (1, 4, 7, 8, 10-14, 17, 18, 20, 21, 23-26, 29, 31, 38-48,
50-58, 60-63) have been published describing hypersensitivity reactions after
occupational exposure to penicillins. Most of the subjects were employed in
pharmaceutical production, health care or veterinary medicine. The hyper-
sensitivity reactions are of Type IV (allergic contact eczema) and Type I (IgE-
mediated allergy) according to the classification system of Coombs and Gells
(49). A case of penicillin-induced alveolitis has also been described (13).
Type I reactions are characterized by one or more symptoms or diagnoses,
including urticaria, allergic rhinitis, sneezing, itching, conjunctivitis, angioedema,
21
digestive disorders, breathlessness, wheezing, asthma and anaphylactic shock.
However, it is not always possible to show that IgE antibodies are involved
in penicillin-induced immediate hypersensitivity reactions with exposure via
respiratory passages or skin, and a still poorly understood non-IgE mediated
immunological mechanism has been proposed (for more information refer to the
Criteria Document, Reference 37). Further, a non-immunological mechanism,
such as irritation caused by dust, can cause some similar symptoms (37).
Two studies giving exposure levels are described below. A few of the more
informative case reports are described in the text and presented in Table 3.
More case reports are described in the Criteria Document (37).
A NIOSH report (not vetted) (23) describes a study of lung function and
occurrence of asthma-like symptoms (questionnaire) in workers exposed to
penicillin powder and granules in a pharmaceutical factory. Four different
penicillins (not further specified) were handled. Total dust was measured with
personal monitors (see above). The 36 penicillin-exposed subjects (26 women and
10 men) were divided into three exposure groups based on job description: high (n
= 10; 5.97 mg/m3, range 2.48 – 12.47), medium (n = 7; 0.50 mg/m3, range 0.08 –
1.48) and low (n = 19; 0.29 mg/m3, range 0.12 – 0.45). Attacks of breathlessness
and wheezing were more prevalent in the penicillin-exposed subjects (15 of 36;
42%) than in controls (2 of 27; 7%) consisting of 27 employees (23 women and 4
men) in the same factory who were not exposed to penicillin and whose total dust
exposure was 0.30 mg/m3 (0.20 – 0.74). When only the women in the groups were
compared, there were also significantly higher prevalences of chronic cough (13
of 26 = 50%; controls 2 of 23 =9%), wheezing (14 of 26 = 54%; controls 2 of 23 =
9%) and breathlessness (9 of 26 = 35%; controls 1 of 23 = 4%). No dose-response
relationship between asthma-like symptoms and exposure to penicillin dust could
be identified, but the authors point out that several persons in the low-exposure
group had previously worked in high-exposure parts of the factory but had been
transferred for health reasons. Lung function tests (FEV1) given before and after
a workshift showed no difference between the exposed groups or between these
groups and controls. The authors could not definitely state that asthma due to
penicillin exposure occurred in the factory, since no effect was shown by the
lung function tests. However, some of the workers with symptoms used broncho-
dilators during their workshifts, and spirometry measurements were taken 6 hours
after the beginning of exposure – possibly too early to show a reduction in FEV1
(23).
Employees (169 volunteers of a total of 319) in a factory producing synthetic
penicillins were studied by Shmunes et al. (61) to ascertain whether there were
any correlations between immunological reactions, allergy symptoms and
penicillin levels in the factory. Air concentrations of ampicillin were measured
with personal monitors. The samples were collected on a millipore filter and
quantified by the bioassay method described in Garth et al. (19). The volunteers
were divided into 4 exposure groups: group A (n = 62) was exposed to <0.1
mg/m3, group B (n = 49) to 0.1 – 9.9 mg/m3, group C (n = 42) to 10 – 263 mg/m3
and group D (n = 16) was exposed periodically. The workers were interviewed,
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and only symptoms that appeared or became more pronounced since they
were hired were noted: 67 persons reported one or more symptoms meeting
this criterion. The most common symptoms were local rashes, runny noses with
sneezing, general itching and itchy eyes. A few also reported swollen eyes, face
and lips, urticaria, wheezing (2 persons), chronic diarrhea, “black hairy tongue”
and/or eczema. Symptoms were significantly more frequent in groups B and C
than in group A. There was also a significant correlation between symptoms and
the occurrence of penicillin-specific IgG and/or IgM antibodies. On the other
hand, no correlation was seen between the symptoms and duration of employ-
ment, age, or most recent known therapeutic use of penicillin. Prick tests with
PPL (penicilloyl polylysine) were negative, and intradermal tests were weakly
positive for one person and yielded unclear results for a few others. One of 9
patch-tested persons with eczema had a positive reaction to the penicillins he
worked with (61). The authors point out that the highest measured dust levels
were several times the threshold limit for inert nuisance dust (15 mg/m3) and that
this alone may have triggered most of the reported symptoms (rash, runny nose
with sneezing, generalized itching and itchy eyes) via a non-immunological
mechanism (61).
Three cases of penicillin sensitization are described in an article by Reisman
and Arbesman (46). Case 1 is a woman who for 5 years distributed penicillin
tablets to patients in a mental hospital. For 8 weeks she had been suffering from
nasal congestion, rhinitis, generalized itchiness, conjunctivitis, coughing and
wheezing at work. The symptoms appeared only while she was at work, beginning
after about 30 minutes and becoming more severe during her shift. The last time
she had received parenteral penicillin was three years previously. Intradermal
tests with benzylpenicillin and PPL were positive (for benzylpenicillin strongly
so), and within 5 minutes she had a severe systemic reaction with generalized
urticaria, rhinitis, conjunctivitis, coughing and breathlessness. Case 2 describes
a nurse who developed generalized urticaria within 10 minutes of swallowing
two penicillin tablets. She responded rapidly to treatment with adrenaline and
antihistamine. She had previously been treated with penicillin on several
occasions without developing symptoms. Several weeks after this first reaction
she began to develop generalized urticaria every day at work. Her duties included
distributing medicine for oral use, but not giving injections. Intradermal tests with
benzylpenicillin and PPL were strongly positive. Case 3 describes a male farmer,
an atopic with allergic rhinitis and asthma, who on three occasions developed
generalized itching, a swollen finger and asthma shortly after having injected
cows with penicillin. He had once developed severe urticaria on his face right
after his wife, who had just taken a penicillin tablet, touched him with her hand.
The man had previously been treated numerous times with penicillin and had no
problems. He had also been treating his cows with penicillin for some time (not
specified) since his most recent penicillin treatments, and had no problems. An
intradermal test with PPL was strongly positive. The authors conclude that the
woman in the first case had been sensitized by repeated inhalation of low concen-
trations of penicillin and the woman in the second case had been sensitized by
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either parenteral or inhalation exposure to penicillin. The man in the third case
was probably sensitized by skin contact and inhalation of penicillin when he gave
the penicillin to his cows. Penicillin-specific IgE antibodies were found in all
three patients (46).
Three men who were exposed to ampicillin and other penicillins by skin
contact and inhalation during ampicillin production developed rhinitis and asthma
symptoms after about 2 years on the job. None of them had a history of asthma,
hay fever or allergy to medicines before the exposure. Provocation tests with
inhalation of one or more of the tested penicillins yielded an asthmatic reaction
of the late type (3 to 16 hours after exposure) with FEV1 reduction of more than
15%, and eosinophilia in the blood within 24 hours. Oral provocation triggered
a late asthma reaction in two of the men, one of whom also developed urticaria.
Prick tests with penicillins were negative (12). The authors concluded that the
men had developed asthma as a result of inhaling penicillin dust, but no infor-
mation is given on possible therapeutic penicillin use during the presumed two-
year latency period.
In an Italian dermatology clinic, 3,758 eczema patients were patch-tested during
1968 – 1977, and 4,472 in 1978 – 1983, with a series of pharmaceuticals including
penicillin. The proportion of positive patch tests for penicillin dropped from 4.6%
in the first period to 0.6% in the second (1).
Among patients with work-related contact eczema who were patch-tested in a
Polish dermatology clinic, a maximum of positive patch tests for penicillin was
seen in the 1981 – 1985 period (9.8%). The percentage of positive patch tests then
began to drop, and in 1996 – 1998 was down to 0.7%. The drop closely followed
the reduction in use of benzylpenicillin, from 21 million capsules annually in 1989
to 4 million in 1998 (58).
It was judged from a review of medical histories that 39 workers exposed
regularly to bacampicillin in a Swedish pharmaceutical production plant had
developed bacampicillin hypersensitivity in the 1990 – 1998 period. Sixteen
of the cases reported symptoms indicating Type 1 hypersensitivity (rhinitis),
19 indicating contact allergy (eczema), and 4 indicating both Type 1 and contact
allergy. Patch tests with bacampicillin yielded 11 positive responses in the first
group, 16 in the second group, and 3 in the third group. Prick tests were positive
for 5 of 8 tested in the first group and 1 of 2 tested in the third group. In a
lymphocyte transformation test (LTT) with bacampicillin, 87% of the 39 had a
positive response (8). No air concentrations were given in the article, but there are
some unpublished data. In 1977 air concentrations (total dust) were 2 to 90 mg/m3
measured around charging of benzylpenicillin, and 0.4 to 1.2 mg/m3 around
removing the bacampicillin for drying. The production process was changed to
a closed system in several steps implemented between 1995 and 2002. In 2001
concentrations were 16 and 0.1 mg/m3 respectively, and in 2003, 0.3 and 0.1
mg/m3 respectively. No new cases of hypersensitivity to penicillin have been
recorded at the company since the production process was redesigned (personal
communication 2005, Marie Haag Grönlund, AstraZeneca).
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Table 3. Summary of some case reports of hypersensitivity reactions caused by penicillins.
Exposure situation
or profession
Number
of cases
Effects/test results  Ref.
Synthesis of
pivmecillinam and
pivampicillin
14 Frequently recurring symptoms such as rhinitis, eczema and urticaria
in 6 employees working with penicillin synthesis, and rhinitis and
conjunctivitis in 8 employees who packaged penicillin powder
containing flavor additives. Three had symptoms of asthma. Latency
time between start of exposure and appearance of symptoms varied
considerably, from 1 week up to 5 years. Symptoms became more
severe when exposure increased. Basophil histamine release tests
were positive for 5 of the 14, and patch tests with various penicillins
were positive for 4 of 9 tested.
38
Production of
pivmecillinam and
pivampicillin
45 In a factory producing penicillins, medical examinations and patch
tests were given to 45 employees with eczema, especially on hands,
arms, calves and face. All of them had positive results for at least
one of the tested penicillins, and 29 for two or more of them; 5
reported symptoms of asthma (mostly of the late type), 17 reported
hay fever symptoms, and 3 reported both types. Latency time
between start of exposure and appearance of symptoms ranged
from 1 week to 1 year. The factory was highly contaminated with
penicillin dust. The total number of employees at the factory is not
reported.
39
Penicillin
production
1 One case of penicillin-induced allergic alveolitis with airways
hyperreactiviity has been described: a 63-year-old woman who had
been exposed to penicillin in a pharmaceutical factory for 12 years.
After 5 years of employment she developed (after an hour or two at
work) daily problems with coughing, breathlessness, wheezing,
chest tightness and itching rash, sometimes accompanied by
conjunctivitis and rhinitis. The symptoms became more severe with
time. She was examined 18 months after she quit her job. An
intradermal test with PPL yielded a reaction after 6 hours. A serum
precipitin test was negative. An inhalation provocation test with
benzylpenicillin (10 mg/m3 for 60 minutes) gave no immediate
reaction, but after 2 hours coughing, chest tightness and wheezing;
FEV1 dropped by 12% and FVC by 20%. DCO dropped by 20% after
6 hours. There was no reaction to provocation with lactose alone. A
transbronchial biopsy showed slight fibrosis. A metacholine test
given 24 hours after the provocation test showed hyperreactive
airways. A metacholine test given a little over a year later was
normal.
13
Nurse 1 A nurse developed facial erythema with severe swelling and itching
a few hours after she accidentally sprayed her face with a solution of
benzylpenicillin while she was preparing an injection. A patch test
with benzylpenicillin was positive, a prick test negative.
45
Nurses 21 In a patch-test study of 333 nurses, 21 had positive reactions to one
or more of the tested penicillins. Although it is not stated clearly in
the article, the 333 nurses probably had eczema.
56
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Table 3. Cont.
Exposure situation
or profession
Number
of cases
Effects/test results  Ref.
Nurses 7 The study describes 6 nurses who had reactions after being in a room
where penicillin injections were given. Four had anaphylactic shock,
and one of these also had urticaria. One of the other two developed
urticaria and rhinitis, the other urticaria only. A seventh nurse is also
described, whose face became swollen after she inadvertently
sprayed penicillin on it while preparing an injection. Two days later
her hands began to itch, the urticaria spread, and her blood pressure
fell drastically 10 minutes after she had prepared a penicillin
solution.
53
Veterinarians 6 Six veterinarians with eczema, primarily on the hands, arms and
face, had positive patch tests for penetamate (penicillin used on cows
for local treatment of udder inflammation); 3 were also positive for
benzylpenicillin.
24
Veterinarians 23 Of 37 veterinarians with debilitating eczema, 23 had positive patch
tests for pentamate and 5 for benzylpenicillin.
26
Veterinarians 5 Of 34 veterinarians who had or had had eczema, 9 were judged to
have occupation-related positive patch test reactions. Five of the 9
were positive for penetamate; 4 of these were also positive for other
penicillins.
14
Nurse 1 A nurse developed eczema on her hands and in skin creases after
about 5 years of work at a hospital. She also developed urticaria and
shortness of breath after skin contact with a mezlocillin solution.
Increasing discomfort caused her to change jobs 4 years later. An
open patch test with mezlocillin produced a local urticarial reaction
after 10 minutes. After 2 and 3 days an eczematous reaction was
observed. Benzyl- and phenoxymethyl penicillin-specific IgE
antibodies were identified. According to the authors, she was
probably sensitized by occupational exposure.
29
Nurse 1 A nurse, after 15 years in the job, opened a package of amoxicillin
and rapidly developed facial edema, rhinoconjunctivitis, breath-
lessness, and difficulty in speaking and swallowing. Prick tests
were positive for amoxicillin and ampicillin. IgE antibodies were
identified for benzyl- and phenoxymethyl penicillin, but not for
amoxicillin or ampicillin. A histamine liberation test was positive
for amoxicillin but not for ampicillin.
10
Nurses,
veterinarians
11 Of 14,689 patients who were examined for suspected contact
allergy at a Belgian dermatology clinic in the 1978 – 2001 period,
occupational allergic contact eczema was diagnosed in 33 persons
who worked in health care: 11 of them (7 nurses, 4 veterinarians)
had positive patch tests for one or more penicillins.
20
Livestock
breeder
1 A livestock breeder developed eczema on hands, face and both sides
of the neck. His eczema became more severe every time he prepared
feed, which involved mixing the feed with various antibiotics. Patch
tests were positive for penicillin and some other antibiotics.
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Experimental studies
No published animal studies on effects of penicillin inhalation were found in the
literature searches (37).
The contact allergenic potential of benzylpenicillin has been studied with the
“human maximization test” (32). Benzylpenicillin was classified on different
occasions as a moderate or strong contact allergen (Grade III allergen; 32 – 52%
sensitized, or Grade IV allergen, 56 – 80% sensitized) for humans (32). When
benzylpenicillin was tested further in a modified test, the “reduced maximization
test”, it was found that repeated exposure to a concentration as low as 0.1% in
vaseline could cause sensitization (33).
The contact allergenic potential of penicillins has been quantified in the
Guinea Pig Maximization Test (GPMT). In four studies (3, 22, 34, 35) benzyl-
penicillin was classed as a Grade V allergen (81 – 100% sensitized animals) on
the Magnusson-Kliegman scale (35), and in a fifth study (36) as a Grade IV
contact allergen (65 – 80% sensitized animals). Bacampicillin and cloxicillin were
also classified as Grade V allergens in these tests (34). There was a pronounced
cross-reactivity between benzylpenicillin and bacampicillin, whereas the cross-
reactivity between cloxacillin and the two others was more moderate (34).
For further details see (37).
Benzylpenicillin has also been tested in mice with the Local Lymph Node
Assay (LLNA), and was found to be a potential skin sensitizer (3, 30). The results
with mice indicated a weaker allergenic potential for benzylpenicillin than
indicated by the above-described tests with humans and guinea pigs (37).
Other effects
A Russian study (64, cited in 37 and 61) reported changes in the normal intestinal
flora of antibiotic-exposed workers. Fecal cultures from 441 workers were
examined. Workers exposed to penicillins had a higher frequency of changes in
bacterial flora (92%) than workers exposed to streptomycin (81%) or tetracycline
(76%). There was also a clear growth of Candida and reduced amounts of
vitamins C, B1 and B2 in their bodies.
Carcinogenicity
In 1990, the IARC classified ampicillin (trihydrate and sodium salt), with oral
and parenteral administration, in Group 3: “ampicillin is not classifiable as to its
carcinogenicity to humans.” (28).
Dose-response / dose-effect relationships
There are no data on which to base a dose-response or dose-effect relationship for
effects indicating possible Type 1 sensitization, including asthma. Shmunes et al.
(61) reported that workers exposed to ampicillin concentrations of 0.1 to 9.9
mg/m3 in a factory producing synthetic penicillins had a significantly higher
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frequency of allergy symptoms than a comparison group exposed to less than 0.1
mg/m3. In an unvetted report (23) a higher frequency of asthma symptoms was
reported in workers exposed to 0.29 mg penicillin dust/m3 (0.12 – 0.45 mg/m3),
measured as total dust, than in a control group. None of these studies contains
clear evidence of a dose-response relationship between penicillin dust and asthma
symptoms. None of them can be used to identify a level that is sensitizing.
Penicillin-induced allergic alveolitis is described in one study (13), but no
exposure levels are given.
The contact-sensitizing potentials of penicillins have been tested experimentally
with both humans and animals, and found to be high. Penicillins as topical medi-
cation were discontinued at an early stage because too many patients became
sensitized (15).
Conclusions
Occupational exposure to penicillins via inhalation or skin contact can cause
sensitization and symptoms including asthma, urticaria and anaphylaxis. There
are no reliable data on exposure levels that may cause sensitization.
Occupational skin exposure to penicillins can cause allergic contact eczema.
Experimental data indicate that the risk of sensitization from skin contact is high.
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Consensus Report for n-Hexanal
March 29, 2006
This document has its origin in a project described in a report from the
Västernorrland County Council (45) and a subsequent publication (46). The
Council report describes hexanal formation in conjunction with the production
and storage of wood pellets. Other sections are based on literature published in
the 2002 – 2005 period and found in searches on ToxNet (Nov. 7, 2005) and
Entrez-PubMed (Jan. 20, 2006).
Chemical and physical data
CAS No: 66-25-1
Synonyms: aldehyde C-6, caproaldehyde, capronaldehyde,
 1-hexanal, hexane aldehyde, hexylaldehyde
Formula: CH3-(CH2)4-COH
Molecular weight: 100.18
Density: 0.814
Boiling point: 131 °C
Melting point: -56 °C
Flash point: 32 °C
Vapor pressure: 1.5 kPa (25 °C)
Saturation concentration: 14,882 ppm (25 °C)
Solubility (water): 5.64 g/l (30 °C)
Log Poctanol/water 1.78
Conversion factors: 1 mg/m3 = 0.245 ppm; 1 ppm = 4.1 mg/m3
Hexanal is an aldehyde that occurs or is formed naturally in living cells of both
animals and plants. Hexanal can be broken down rapidly, for example in human
cells. The molecule is reactive and binds to proteins and other substances in the
cells (14, 15, 33). It is attributed with irritating qualities (2). Literature that spe-
cifically describes the toxicological effects of hexanal on humans or animals is
still relatively scarce, although exposure and the number of exposed people is
increasing with the use of wood pellets as fuel in Sweden and elsewhere.
In an exposure chamber study, subjects noticed the smell at 2 ppm (13). For
squirrel monkeys and pigtail macaques the odor threshold is below 1 ppm, and for
some individuals below 1 ppb, which shows a well developed olfactory perception
for hexanal and other aliphatic aldehydes (27).
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Occurrence
Hexanal occurs naturally in food, and is reported to occur in at least 100 different
foods (apples, strawberries, tea, tobacco, coffee etc.) (16): the article gives a
maximum concentration of 300 mg/kg (3 mmol/kg). The odor of hexanal has
been described as “grassy” or “leafy” (40). Hexanal has been identified in several
substances, including vapors from cooking oil (50). Hexanal can be formed in
foods when they spoil (35) and can occur in drinking water (0.2 – 0.8 μg/l) (26).
Hexanal is used in food as a flavor additive, in organic syntheses, and in rubber,
paint, insecticides etc.
A study of hexanal levels in Paris homes revealed large variations. The average
value was 33.5 μg/m3 (8.2 ppb) but the upper 95th percentile was 150 μg/m3 (37
ppb) (7).
In a recently published study it was shown that hexanal is formed during
storage of wood pellets – probably as a product of ongoing autooxidation (46).
Concentrations above 24 ppm (100 mg/m3) were measured in pellet storage areas
at a factory. On a service walkway the concentration was 83 mg/m3 and in the
tractor cab at loading the measured concentration was 4.3 mg/m3. Home heating
with wood pellets is becoming increasingly popular in Sweden, and 714,000 tons
of wood pellets were produced in Sweden in 2001. Levels of 0.8 mg/m3 have been
measured in basements near the furnace room in dwellings (46). Hexanal is also
formed when sawdust is autoclaved for use as litter for laboratory animals (23).
Hexanal can be formed in the body tissues during lipid peroxidation (17, 33,
49). Omega-6 fatty acids give rise to hexanal. Lipid peroxidation is a patho-
logical/toxicologic process that can be initiated in biological tissues by oxidative
stress, which in turn can be initiated by several different kinds of xenobiotics.
Hexanal, and other aldehydes that are formed by oxidative breakdown of
polyunsaturated fatty acids, can be used as indicators that lipid peroxidation
has occurred in a tissue. There are several such studies.
Hexanal has been identified in human adipose tissue, but quantitative data are
not reported (36). Hexanal occurs normally in exhaled air from humans (about
18 nmol/l condensate). Smokers have higher levels, as do persons with chronic
obstructive lung disease (8). Saliva also contains hexanal (1, 8, 9). Levels in blood
were measured in a Chinese study: they ranged from 34 to 180 nM (3.4 – 18 μg/l)
in 7 healthy subjects and from 1900 to 5500 nM in ten treated lung cancer patients
(11, 28).
It may be of particular interest that high amounts of hexanal are found in
atherosclerosis plaque (18), where it may play some role in the development of
the disease (see below).
Exposure pathways, uptake, excretion
Occupational exposure to aldehydes can occur via inhalation, skin uptake and
oral uptake (38). The primary exposure pathways for most of the population are
probably inhalation and intake in food and water. The average intake of hexanal
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for a Dutch population was estimated to be 16.5 μg/day (6.0 mg/year) (21). No
measurements of uptake were found.
When mice were given intravenous injections of hexanal (68 mg/kg) plasma
levels dropped within a few minutes but then remained fairly stable (at about 170
nmol/ml) for two hours. In lungs the concentration peaked within 30 minutes and
then began to drop (49).
Hexanal levels in 24-hour urine samples from healthy controls were around
2 μmol (200 μg) (37), and did not increase with an hour of physical exercise.
Metabolism
No in vivo studies of metabolism were found. In general, aldehydes can be broken
down to the corresponding acids via metabolic oxidation. The process can be
catalyzed by aldehyde dehydrogenase (ALD). It was shown in an in vitro model
that ALD protects the cells against hexanal-induced inhibition of cell growth (47),
and a form found in humans has been found to be highly active. In an earlier study
it was shown that hexanal was oxidized by another isoform of ALD, which is
induced by TCDD (2,3,7,8-tetrachloro-dibenzo-p-dioxin) and expressed in rat
liver tumors (31).
No effects on glutathione levels in mouse lungs were seen after injection of
68 mg hexanal/kg b.w. (49).
Reduction of hexanal to hexanol has been observed in rat brain, and it has
also been shown that hexanal can be condensed with pyruvate to acyloins and
3-hydroxyoctane-2-one by the activity of pyruvate dehydrogenase (24).
Toxicity
There are no long-term toxicity studies of hexanal.
Human data
Low-molecular aldehydes in general are reported to be strongly irritating to
mucous membranes in nose, mouth and upper respiratory passages. No specific
information on the effects of the longer-chain hexanal on humans was found in
Patty’s Industrial Hygiene and Toxicology (2).
In one study, volunteers (21 – 28 years old) were exposed to 0, 2, or 10 ppm
hexanal for two hours on three occasions at least 2 weeks apart (13). They were
not told the order of the exposures. They graded their symptoms before, during
and after the exposures by markings on ten 10-cm visual analog scales (VAS),
one for each symptom group. The scales were pre-printed with descriptions of
increasing severity. The ten symptom groups were: “eye discomfort: burning,
irritated or running eyes; nose discomfort: burning, irritated, or runny nose;
throat or airway discomfort; breathing difficulty; solvent smell; headache;
fatigue; nausea; dizziness; feeling of intoxication”.
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Lung function, nasal swelling, blinking frequency and inflammation markers
(CRP and IL-6) in blood samples (taken 3 hours after the end of exposures) were
also measured. At 10 ppm the subjects reported (in addition to solvent smell) eye
discomfort (16.5 mm/100 mm) and other symptoms (16.5 mm on the VAS did not
exceed the verbal rating “somewhat”). Blinking frequency was also significantly
higher at 10 ppm. The authors concluded that 10 ppm hexanal has a weak
irritating effect, and in this study it was the LOAEL (lowest observed adverse
effect level) and 2 ppm was the NOAEL (no observed adverse effect level).
Animal data
The LD50 for oral administration of hexanal to rats is reported to be 4890 mg/kg
(41).
In an inhalation study from the 1950s (41), rats were exposed to 2000 ppm
hexanal for 4 hours. One of 6 died. In the same study rats were exposed to
“concentrated vapor” for 1 hour and mortality was then 0/6. Hexanal is reported
to be slightly irritating to the eyes and skin of rabbits.
In Grant’s Toxicology of the Eye (20), hexanal is ranked 5 on a 10-point scale
for eye irritation in rabbits.
The RD50 (the concentration that reduces respiratory rate by 50%) for hexanal
inhalation was 1116 ppm for B6C3F1 mice and 1029 ppm for Swiss-Webster mice
(42).
In a large study, male and female rats were given hexanal in drinking water
(calculated intake 0.1, 1.2, 12.6 or 124.7 mg/kg/day) for 4 weeks. There were 10
males and 10 females in each dose group. There were also 2 control groups in the
study, as well as groups of rats exposed to other substances. Organ weights, 18
hematalogical parameters and liver microsome activities were measured. Histo-
logical examinations were made of 26 organs/tissues, including pancreas. All the
rats survived and their growth was not affected at any dose level. The authors
report that treatment-related morphological changes (slight effects on thyroid,
liver and kidneys) occurred only in the high-dose group. There was also a slight
reduction of lactate dehydrogenase activity in serum, but it was not dose-
dependent (26).
Hexanal emitted from autoclaved sawdust in cages for laboratory animals has
been shown to contribute to deaths in pups of genetically modified mice. One
explanation may be that hexanal (4 μg/35 g sawdust) induces Fos expression
(increases the activity of protein that increases cell growth) in certain brain areas
in the dams. This might affect maternal behavior and have an adverse effect on
nursing (22). The exposure level is unknown, as is the relevance to humans.
In vitro data
There are quite a few published studies in which hexanal was tested in various cell
models. A representative selection is reviewed below.
In a study with cultured human endothelial cells from umbilical veins, hexanal
was not toxic (concentrations up to 0.1 mM) in relation to unsaturated aldehydes
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and especially in relation to linoleic acid hydroperoxide (25). At concentrations
between 10 and 30 mM hexanal a large portion of primary hepatocytes, from both
rats and humans, died (trypan blue exclusion test). All the rat hepatocytes died at
a concentration of 100 mM (32). Growth of fibroblasts from Chinese hamsters
(V79) was inhibited by 0.1 mM or more (47). Formation of the inflammatory
signal substance TNF-α was inhibited in human macrophages by lipid peroxi-
dation products. Hexanal was one of the less potent inhibitors, but concentrations
of 0.2 to 1.0 mM had some effect (19). Hexanal (50 μM) increased expression of
the CD36 gene in macrophages (48). In comparisons with other lipid peroxidation
products, hexanal has a milder but still toxic effect, for example by reducing ATP
levels (4, 12).
In a study in which β-cell islands isolated from rat pancreas were exposed to
various combinations of inflammatory cytokines, hexanal was found to be one of
the substances formed in these cells in response to oxidative stress. It was also
shown that low concentrations of hexanal (0.001 – 0.2 mM) reduced insulin
production and damaged the cells (44). In a later study (34) on a similar model
it was shown that hexanal (0.1 mM) yielded a fairly weak effect on insulation
production (in comparison to other lipid peroxidation products). The effect
reported at the lowest concentration used by Suarez-Pinzon et al. (44) was not
confirmed. A search (November 5, 2004) in the cited articles gave no indication
that hexanal’s toxicity to β-cell islands was studied further.
Smooth muscle cells from human umbilical cord were used in a model focused
on cell communication (gap-junction intercellular communication, GJIC) and
atherosclerosis. A dose-dependent inhibition was induced by a potent lipid
peroxidation product, and hexanal also had some effect. The effect was not dose-
dependent, however, and GJIC was only slightly reduced in the dose interval
0.005 – 0.05 mM (10).
Hexanal has been identified in plaque from sclerotic blood vessels (18). It has
also been shown that the cholesterol-reducing medicine simvastatin reduces the
amount of hexanal in the plaque, raising the question of whether hexanal and
other lipid peroxidation products may play some role in atherosclerosis. In further
studies, the group examined the induction of the glycoprotein TF (tissue factor),
via Fos activation, in smooth muscles from blood vessel walls (5). It was found
that 5 μM hexanal was a powerful inducer of TF. Earlier studies reported that
TF can stimulate blood clotting after e.g. plaque rupture (43), and the authors (5)
conclude that endogenously formed hexanal may function as a signal substance
that can contribute to the occurrence of heart infarct, stroke etc.
Genotoxicity, carcinogenicity
The effects of various aldehydes on DNA cross-linking and single-strand breaks
(SSB) were studied using V79 cells (29). Hexanal (0.5 – 4.5 mM) was one of the
substances inducing single-strand breaks. Two of the same authors are in a group
that later published further genotoxicity studies (3), this time on resistance
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development in V79 cells to 6-thioguanine or ouabain (as measures of geno-
toxicity). They concluded that hexanal is mutagenic in concentrations around
3 – 30 mM. In subsequent studies with hepatocytes from rats and humans (32) it
was shown that 30 mM has some effect on DNA (unscheduled DNA synthesis,
UDS) in rat hepatocytes, but at this concentration half of the cells died. Fewer
of the human cells died, and elevated UDS was not seen. Other weaknesses
of the studies are that only two cell batches were used and that the limit for a
clear positive response was not reached. The group has now concluded that the
probability of genotoxic effects on humans is negligible: that hexanal is at most
weakly genotoxic and that damaging concentrations are highly unlikely to occur
in human tissues. They were probably referring primarily to endogenous hexanal,
but inhaled hexanal probably can not generate millimolar concentrations in cells
(e.g. nasal mucosa) either.
A Salmonella strain (TA104) that is particularly sensitive to lipid peroxidation
products was used in a genotoxicity study: hexanal was not mutagenic (30). A
risk assessment survey on the carcinogenic potential of aldehydes (16) makes
no reference to the above publications on genotoxicity, and treats hexanal as a
substance for which there is no relevant data.
No carcinogenicity studies were found.
Effects on reproduction
In an in vitro study with human spermatozoa, hexanal was shown to inhibit
fructose metabolism. The inhibiting concentration was about 0.3 mM (39). In a
later study of spermicides (6) it was shown that the mobility of the sperm was
inhibited at a hexanal concentration of 0.1% (= 1 g/liter; 10 mM).
Dose-effect / dose-response relationships
Earlier, non-quantitative data indicate that hexanal can be irritating to mucous
membranes and skin. A recently published exposure chamber study with healthy
subjects reports uncertain effects at 2 ppm and irritation, including increased
blinking frequency, at 10 ppm (13).
The RD50 (the concentration that reduces respiratory rate by 50%) for hexanal
has been reported to be about 1000 ppm for mice (42). RD50 is used as a measure
of sensory irritation in airways. The ACGIH threshold limit values based on
irritation are generally about 3% of the RD50 value. For hexanal this would be
about 30 ppm.
There are no long-term animal studies of inhalation exposure, but a study in
which animals (4 dose groups) were given hexanal in drinking water reports a
LOAEL (slight morphological changes in thyroid, liver and kidneys) of 125 mg
hexanal/kg b.w./day (26).
In vitro studies indicate that hexanal is relatively non-toxic to many types of
cells. In most of the studies the lowest concentration yielding cell death is a bit
below 1 mM (about 100 mg/l), a concentration that may have been reached with
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the highest dose (1000 mg/l) in the drinking water study (26). One cell study,
however, found that hexanal can be toxic to the insulin-producing cells in the
pancreas at concentrations as low as 0.001 mM (44). It is possible that these cells
are particularly sensitive to hexanal, but in the drinking water study there were
no reported effects on parameters such as blood glucose after the 4 weeks of
exposure. It can also be noted that no confirmation or commentary on this finding
was found in a search (November 4, 2005) of subsequently published literature.
A recently described effect of hexanal pertains to its possible role in athero-
sclerosis and its complications (5). In a cell model, it was shown that 5 μM
functions as a signal mediator and may contribute to blood clot formation.
The relevance in vivo is unknown, as is the air concentration that can yield
sufficiently high blood content.
Early in vitro studies reported that hexanal could be genotoxic. It should be
pointed out that the concentrations were high and the effects small, and that the
results could not be confirmed (according to the literature reviewed for this
Report) by other laboratories (30). In the latest work on hexanal published by
this research group, the authors themselves conclude that hexanal’s possible
genotoxicity is negligible for humans (32), (see Table 1).
Conclusions
There are no long-term studies, and the available information is not sufficient to
establish a critical effect of occupational exposure to hexanal. Exposure chamber
studies have shown that hexanal is irritating at an air concentration of 10 ppm.
38
Table 1. Dose/concentration – effect relationships for exposure to hexanal.
Type of study Exposure Effects      Ref.
Human study
  Exposure chamber
  study
2 ppm (8 mg/m3)
2 hours
No clear effects 13
10 ppm (40 mg/m3)
2 hours
Irritation with increased blinking
frequency
Rat study
  Hexanal in
  drinking water
12,6 mg/kg/day
4 weeks
NOAEL for most endpoints 26
125 mg/kg/day
4 weeks
Slight effects on thyroid, liver, kidneys
Mouse study
  Inhalation 1116 ppm (4.6 g/m3)
(Swiss-Webster)
1029 ppm (4.2 g/m3)
(B6C3F1)
10 minutes
RD50 (the concentration that reduces
respiratory rate by 50%)
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In vitro studies
  β-cells (rats) 0,001 mM LOAEL for reduced insulin production
(results not confirmed, and contradicted
by other data)
44
  Human vascular
  smooth muscle
  cells
0,005 mM Induction of TF 5
  Hamster V79
  fibroblasts
0,1 mM Inhibited growth 47
  Human
  spermatozoa
0,3 mM Inhibited fructose metabolism 39
  Mutagenicity
  studies
3-30 mM Slight mutagenicity with high
cytotoxicity; dubious value
32
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Consensus Report for Nitrous Oxide
(laughing gas)
June 7, 2006
This report is based primarily on a criteria document (28) compiled at the
request of the Swedish Criteria Group for Occupational Standards, supplemented
by a review of recent literature. It updates the consensus report published in 1981
(39).
Chemical and physical data. Uses
CAS No.: 10024-97-2
EG No.: 233-032-0
Synonyms: nitrous(I)oxide, dinitrogen oxide, laughing gas
Earlier name: nitrogen oxidul
Formula: N2O
Molecular weight: 44
Density (kg/m3): 1.98 (0 °C, 1 bar)
Relative density: 1.5 (air = 1.0)
Boiling point: - 88.5 °C
Conversion factors: 1 ppm = 1.83 mg/m3 (20 °C, 101.3 kPa)
1 mg/m3 = 0.55 ppm (20 °C, 101.3 kPa)
1% = 10,000 ppm
Other data: 1 liter of liquid yields 662 liters of gas at atmospheric
pressure and a temperature of 15 °C.
The gas is heavier than air; there is a risk that it
will accumulate in enclosed spaces.
Oxidating.
The gas does not burn but supports combustion.
Nitrous oxide (N2O) is a colorless gas with a faint, sweetish odor. It is used as an
anesthetic. It is popularly called laughing gas because of its ability to produce
euphoria.
Occurrence in the workplace
Nitrous oxide was first used as an anesthetic in 1844 (48). It was introduced
in Sweden in the 1860s, and is still a basic component in most combination
anesthesia procedures.
43
Occupational groups exposed to nitrous oxide are operating room staff, mid-
wives, dental surgeons and their assistants. With modern methods of anesthesia
administration, levels in ambient air are generally well below 400 ppm (732
mg/m3) (35, 37). With older administration methods and in poorly ventilated
operating rooms, levels of 400 – 3000 ppm (732 – 5490 mg/m3) have been
registered, with a few peaks as high as 6000 ppm (10,980 mg/m3). For setting
exposure limits, however, the studies of greatest relevance are those of lower
exposures.
Nitrous oxide is also used as motor fuel, but exposure from this use is not
relevant in the present context.
Uptake, biotransformation, excretion
Nitrous oxide has long had widespread use as an anesthetic, and the pharmaco-
kinetics of inhalation have therefore been thoroughly studied: they are well
described by physiologically based pharmacokinetic (PBPK) models (see for
example Reference 44). Nitrous oxide is a small molecule that diffuses rapidly
through cell membranes, and it is therefore rapidly taken up in the lungs and other
body tissues. Since solubility in blood and fat is low, with coefficients of 0.42 for
blood/air (47) and 1.4 for fat/air (57), accumulation in the body, including fatty
tissue, is insignificant, and –– in contrast to many solvent vapors –– increased
workload increases body burden only slightly. After exposure is stopped the
concentration of nitrous oxide in blood drops rapidly, with a half time of about
a minute. The remaining concentration then drops more slowly, with a half time
of about 20 minutes (calculated from information in Reference 44).
Nitrous oxide is excreted in urine, and there is a good correlation between
concentrations measured in air and excreted N2O (35, 38, 56). Biological
monitoring of nitrous oxide has therefore been proposed as an alternative
to air monitoring for the purpose of risk assessment. Urine samples for this
purpose should be taken both before and after exposure.
No studies on the metabolism of nitrous oxide were found.
Toxic effects
Effects on blood-forming organs
Animal experiments
In experiments in which rats were exposed to high concentrations of nitrous oxide,
20% (200,000 ppm; 366,000 mg/m3) or more, blood profiles were affected. Rats
exposed to 1% nitrous oxide (10,000 ppm; 18,300 mg/m3) 6 hours/day, 5 days/week
for up to 6 months (to resemble the occupational exposure of a dental surgeon) had
no observable changes in bone marrow, but they had significantly lower hemo-
globin levels (21).
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Human data
Patients treated by breathing a mixture of 50% oxygen and 50% nitrous oxide
constantly for 14 to 17 days developed several morbid changes in their blood
profiles (42). The authors point out that continuous N2O treatment can result in
acute bone-marrow aplasia (loss of blood-forming function). The changes are
reversible, however, with return to normal blood profile when the treatment is
stopped.
Similar results were obtained in another study of patients who were treated with
50% oxygen and 50% N2O for either 24 hours or 5 to 12 hours (2). Nitrous oxide
interacts with vitamin B12-dependent enzymes, which may result in megaloblastic
anemia (characterized by abnormally large erythroblasts – immature red blood
cells) (2). This interaction may also lie behind the occurrence of myeloneuropathy
(neural pain, deterioration of reflexes in arms and legs), see below .
In one study (60), 21 dentists (volunteers) were followed for 3 to 11 weeks.
They wore personal monitors while they were doing work involving exposure.
Bone-marrow samples were taken and other studies were also made during this
period. The time-weighted average exposures to N2O ranged from 159 to 4600
ppm (291 – 8418 mg/m3) and reported exposure times ranged from 0.5 to 27 hours
per week. Blood tests, including B12 and folate, were normal, as were the neuro-
logical tests. However, results of a deoxyuridine inhibition test (a sensitive test
for inhibition of DNA synthesis) were pathological in two and borderline in one
of the 20 subjects given this test. In the two subjects with pathological results,
profiles of peripheral blood showed hypersegmented neutrophils with more than
five nuclei, and in bone marrow there were giant metamyelocytes and slight
melanoblastic changes. There was no clear correlation between exposure (ppm x
hours) and effects. In the three with abnormal test results, the lowest exposure
level at which effects were noted was 1800 ppm (3294 mg/m3) and this dentist had
been exposed for 27 hours per week. The other two had exposures of 1900 and
2500 ppm (3477 and 4574 mg/m3) for 6 and 10 hours per week respectively. The
three dentists with abnormal inhibition tests were among the six subjects who had
exposures above 10,000 ppm x hours per week. The authors concluded that their
study strengthens suspicions that N2O interferes with the metabolism of vitamin
B12.
Effects on the peripheral nervous system
Persons occupationally exposed to nitrous oxide in poorly ventilated dental
offices, or those who abuse the substance for 3 months or longer, have developed
tingling and numbness in extremities, reduced ability to register sensory impres-
sions (especially touch), balance problems etc. Measures of neural conductivity
yielded lower values, possibly due to nitrous oxide’s interference with vitamin
B12-dependent metabolism (43). Since there are no quantitative exposure data,
no dose-response relationships can be given.
There are still people who abuse nitrous oxide, and a few case reports have
been published. Pema et al. (50) describe a case of myelopathy compatible with
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vitamin B12 deficiency in a 31-year-old man who had abused nitrous oxide for
several years.
Effects on the central nervous system
Several laboratory studies have confirmed that nitrous oxide in high doses has
CNS and psychological effects.
Thirty volunteers (male undergraduates) were exposed to either 500 ppm (915
mg/m3) nitrous oxide or air for four hours, and then given function tests (14). Each
person was exposed on one occasion to nitrous oxide and on the other occasion to
air alone. The subjects were exposed in an exposure tent, and the tests were given
immediately afterward. On the group level the only difference between the nitrous
oxide and the air exposure was a lower score on a short-term memory (digit-span)
test.
The same researchers (15) also studied the effect of four hours of exposure to
50 ppm (91.5 mg/m3) nitrous oxide. Twenty volunteers (male undergraduates)
were exposed by breathing through a mask. Ten were exposed first to nitrous
oxide and a week later to air, and the other ten were exposed in reverse order. The
psychometric tests were begun after two hours of exposure and the last one was
given immediately after exposure ended. At the group level, test results after the
nitrous oxide exposure were significantly worse on the 3-minute and 7-minute
audiovisual tests (tests of perception and reaction time), given respectively about
2.75 and 4 hours after the start of the exposure. Another group of 20 persons,
exposed additionally to 1 ppm halothane, had significantly worse results in two
other tests and were better on one test than the group exposed to nitrous oxide
alone.
These results could not be confirmed in other studies (24, 32, 55); however,
these later studies are not directly comparable because the exposures were shorter.
In a similarly designed study (63), 24 volunteers were exposed to either air or
50 ppm (91.5 mg/m3) nitrous oxide in an exposure chamber for 4 hours. Each
person was tested twice, once with and once without nitrous oxide exposure. The
psychometric tests were given during the last 40 minutes in the exposure chamber,
and included an audiovisual task test like the one that showed effects in the study
by Bruce and Bach (15). No differences between the nitrous oxide and air expo-
sures were observed, either in that test or in tests of simple reaction time, four-
choice reaction time, or stressalyzer (63).
Bruce has since published an article (17) in which he states that he does not
consider his results to be valid. “There is no longer any need to refer to our
conclusions as controversial. They were wrong, derived from data subject to
inadvertent sampling bias and not applicable to the general population. The
NIOSH standard should be revised.” In addressing the issue of comparability,
internal and external validity, Bruce (16) suggests that the subjects of his studies,
male Mormons, are unusually sensitive to such substances as anesthetic gases
because of their lifestyle. The external validity of the results can therefore legiti-
mately be questioned. Neither he nor anyone else has criticized or questioned the
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methodology of his studies, and the “sensitive subjects” argument may explain
why other researchers could not confirm the results reported by Bruce and Bach.
Ayer et al. (6) studied 10 dental assistants at work. They were tested before
they began work, after 20 minutes of anesthetic administration, and immediately
after they had finished administering the anesthetic. The assistants were exposed
to an average N2O level of 210 ppm (383 mg/m3) during the 35-minute sessions.
The tests used were the color-naming test, pegboard test and fusion-frequency of
flicker test. None of the tests showed any significant differences between results
obtained before work, after 20 minutes of anesthetic administration or after the
end of the exposure. Twenty dentists were also studied. Ten of them used nitrous
oxide at work: their average exposure was 536 ppm (981 mg/m3), range 150 –
1500 ppm (274.5 – 2745 mg/m3). They were compared with ten unexposed
dentists (5). All of them were tested before beginning to treat a patient, 20 minutes
after the treatment had begun, and immediately after the treatment was completed.
The length of the treatment periods is not reported. The exposed dentists and
the unexposed dentists had equivalent results on the tests they were given: the
Lafayette pegboard test and the Ruesh color naming test. The authors concluded
that their results were in agreement with earlier reports on effects of low con-
centrations of nitrous oxide on psychomotor activity, i.e. that no effect can be
demonstrated, but they mention the possibility that several years of exposure
may have negative consequences.
Lucchini et al. (46) published a study suggesting that exposure to low concen-
trations of nitrous oxide, geometric means for a workweek 50.9 ppm (93.1 mg/m3)
to 54.2 ppm (99.2 mg/m3), yields measurable, reversible effects on reaction time.
The studied group comprised 30 doctors and nurses who worked in operating
rooms for heart surgery. They were followed for a week with exposure to nitrous
oxide and for a week without nitrous oxide exposure. Two exposure-free weeks
passed between the two studied weeks. A group of 20 randomly chosen nurses
and doctors who worked in other parts of the same hospital were used as controls.
The exposed group and the control group were comparable with regard to sex
ratio, age, alcohol consumption and smoking habits. Exposure to nitrous oxide
was measured in the breathing zone with passive dosimeters during the three-hour
exposures. The measured effects were simple reaction time and serum prolactin
and cortisol. When the exposed group was compared with controls, there were
significant differences in simple reaction time and serum prolactin measured after
work on the last day of the workweek. For the exposed group there was also a
significant difference between results after working for a week with exposure
and results after the unexposed week. The study reports only exposure to nitrous
oxide, but the exposures probably included halogenated anesthetic gases. The
authors themselves do not attribute the observed effects to nitrous oxide exposure,
but to “exposure to anesthetic gases.”
There are a few other studies using psychometric tests to quantify effects of
exposure. However, they report such high exposure levels – 30,000 ppm (54,900
mg/m3) or above – that they provide no useful information (3, 20, 26, 30, 62).
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There is a Swedish study reporting an elevated risk of multiple sclerosis in
nurse anesthetists (31). The study covers 90 nurses with MS, identified via ads
in professional journals (Vårdfacket and Reflex). Exposures were determined by
questionnaire and are described only briefly in the article (“...they were exposed to
a wide spectrum of anaesthetics...”). No conclusions on possible effects of nitrous
oxide exposure can be drawn from this study.
Other effects
In a few epidemiological studies (48), elevated incidences of liver and kidney
diseases have been observed among anesthesia personnel (more than one year of
occupational exposure). These studies provide no information on exposure levels,
and it is probable that the exposures also involved anesthesia gases other than
nitrous oxide.
In animal experiments, exposure to nitrous oxide is at such high levels – above
70,000 ppm (128,100 mg/m3) – that the results are irrelevant in a discussion of
occupational exposure limits.
Mutagenicity, genotoxicity, carcinogenicity
Animal experiments
Nitrous oxide was not mutagenic in Ames’ tests, either with or without metabolic
activation and at up to 5 atm overpressure (5 x atmospheric pressure), in various
strains of Salmonella typhimurium (7, 9, 67). Nitrous oxide, either alone or in
combination with halothane, was not mutagenic in tests with Chinese hamster
lung fibroblasts (V79 cells) (59). However, nitrous oxide did increase the number
of nuclei with halothane-induced abnormalities (tripolar and tetrapolar spindles,
double or triple nuclei, micronuclei) in this type of cell (58). Nitrous oxide, either
with or without addition of metabolizing systems, induced no sister chromatid
exchanges in Chinese hamster ovary (CHO) cells (68). A study from 1974
reports a weak positive result in a sex-linked recessive lethal test on fruit flies
(Drosophila melanogaster) (33). Later studies with the same test system have
been negative (40), even when the nitrous oxide was tested in combination with
halothane, enflurane or isoflurane (11). Nitrous oxide is weakly mutagenic to
Tradescantia, and it has been shown to cause aneuploidy and polyploidy (deviant
and multiple chromosome counts) in other plants when they are exposed with
overpressure. It also potentiates the mutagenic effects of ionizing radiation in
cell cultures (8).
There are a few carcinogenicity studies of nitrous oxide (10, 22, 29). Although
all of them were negative, they are too few to allow any definite conclusions on
carcinogenicity.
Epidemiological studies
Several epidemiological studies have reported elevated frequencies of cancer,
especially in lymphatic tissue, among anesthesia personnel (27). None of these
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studies contains information on exposure times or exposure levels. Nor can it
be determined whether these persons were exposed to nitrous oxide alone or
in combination with other anesthetic gases. There are also studies that do not
indicate elevated cancer frequencies in association with exposure to anesthetic
gases. In the study described below (23), no significant increase of total cancer
frequency could be shown for dentists and their assistants. There was a signi-
ficantly higher frequency of cervical cancer among the female assistants with
high exposure, but exposures were not reported.
A good many of the articles on anesthetic gases published in the past few
years have been genotoxicity studies. There are several studies reporting sister
chromatid exchanges (SCE), micronuclei and chromosome aberrations in exposed
personnel (19, 36, 41, 45, 49, 53, 54). The difficulties with these studies are that
the exposure is rarely to nitrous oxide alone and that none of them gives exposure
levels. They thus provide no information that can be used in establishing either
a critical effect or a risk level for occupational exposure to nitrous oxide. In the
study by Hoerauf et al. (36) there was simultaneous exposure to nitrous oxide
and isoflurane. The reported 8-hour time-weighted averages were 11.8 ppm
(21.6 mg/m3) and 0.5 ppm (0.9 mg/m3). The frequencies of SCE in 27 exposed
anesthesiologists and 27 unexposed doctors were compared. All were non-
smokers. There was a statistically significant difference between the two groups.
The difference was still significant (p = 0.03) when exposed men (n = 13) were
compared to unexposed men (n = 18), but there was no such difference for the
women.
Lewinska et al. (45) studied 46 female scrub nurses exposed to nitrous oxide as
well as sevoflurane and isoflurane. The two latter gases were not monitored but it
was reported that they did “..not exceed the adopted TLV of 18 mg/m3”. Nitrous
oxide in the breathing zone was in the range 36 – 2308 mg/m3 (19.7 - 1261 ppm).
The controls were 28 female nurses working in the same hospital but not exposed
to anesthetic gases or other suspected genotoxic substances. The exposed subjects
had significantly higher numbers of micronuclei, and linear regression analysis
showed correlations between the occurrence of micronuclei and both exposure to
nitrous oxide (r = 0.6; p = 0.00007) and number of years in exposed work (r = 0.6;
p = 0.0001). The correlations were based on exposure levels above 500 mg/m3 and
more than 20 years of exposure, respectively. Regression analysis also showed a
correlation between exposure level and frequency of micronuclei. Fluorescence
in situ hybridization (FISH) analysis of chromosome aberrations indicated a pro-
aneugenic effect (aneuploidy).
Effects on reproduction
Animal experiments
Pregnant rats were exposed to 100, 1000 or 15,000 ppm (183, 1830 or 27,450
mg/m3) nitrous oxide, either 8 or 24 hours/day for 4 to 10 days during the second
and/or third week of gestation, and then compared with control groups (25). In the
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two higher dose groups fetal death rates and pregnancies/rat rates where signifi-
cantly different from the controls. In one of three groups exposed to 100 ppm
(183 mg/m3) there was a suggestion of elevated fetal mortality, but there was
no adequate control group.
Rats were continuously exposed to 0.5% (5000 ppm; 9150 mg/m3) nitrous oxide
on days 1 to 9 of gestation and then killed: compared to the controls there were
significantly smaller litter sizes and higher proportions of resorptions. Fetuses in
the exposed group were significantly smaller and had more skeletal anomalies
compared to the unexposed group (64).
Pregnant rats were exposed to 0.1%, 0.05% or 0.025% (1000, 500 or 250 ppm;
1830, 915 or 457.5 mg/m3) nitrous oxide until day 19 of gestation, when they
were killed. The exposures had the following results (65): In the group with the
0.1% exposure there was a statistically significant reduction in the number of
living fetuses, an increase in the proportion of resorptions and in fetuses a higher
proportion of skeletal anomalies, compared with the other groups. No difference
in fetal body weight or sex ratio was observed. The authors concluded that with
constant exposure the critical concentration of nitrous oxide that can cause fetal
death in rats is between 500 and 1000 ppm (915 – 1830 mg/m3).
Vieira et al. (66) performed another experiment similar to the one described
above (65). Here, however, exposures were intermittent – 6 hours/day for 19 days
– and exposure levels were 250, 500, 1000 or 5000 ppm (457.5, 915, 1830 or
9150 mg/m3). The rats were then killed. There were 12 pregnant rats in each
exposure group. No unexposed group is mentioned. In the group exposed to 5000
ppm (9150 mg/m3) there was a statistically significant reduction in the number
of living fetuses, but there were no other differences between the groups. The
authors interpret this observation with reference to their earlier study, and draw
the conclusion that with intermittent exposure the risk of fetal effects is lower
than with constant exposure at the same exposure levels.
Data from epidemiological studies
Many studies in various countries have reported elevated risk of miscarriage in
personnel occupationally exposed to anesthesia gases. These studies, however,
contain too little information on type or level of exposure to be useful for
assessing the health effects of occupational exposure to nitrous oxide.
A meta-analysis of studies reporting spontaneous abortions in women exposed
to anesthetic gases concludes that epidemiological studies indicate an elevated
risk (13). The analysis was based on a review of 19 published studies, 2 of which
were case-control studies. There was no information on either the type(s) of
anesthetic gas or the exposure levels.
Two other survey articles (18, 61) on risks of occupational exposure to
anesthetic gases present the conclusion that the literature does not provide
adequate support for asserting that exposures cause miscarriages or birth defects.
One article (61) reviews 14 studies published in the 1971 – 1982 period, and the
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other (18) reviews 28 articles published in 1973 – 1996. Neither of them contains
information on either type(s) of gas or levels of exposure.
In a Canadian study (34), data from 8,052 persons exposed to anesthesia gases
and 2,525 unexposed persons were collected by questionnaire. There was an
elevated incidence of spontaneous abortion among the exposed women. No
information on types of gas or exposure levels is given.
From the results of a large epidemiological study of dentists and dental
assistants in the United States (in which attrition was about 20%), the authors
conclude (23) that long-term exposure of male dentists to anesthetic gases leads
to an elevated frequency of miscarriage in their wives, and that exposed female
assistants have elevated frequencies of miscarriages and children with congenital
defects. The dental assistants who were exposed to nitrous oxide alone had twice
as many miscarriages and half again as many children with congenital defects as
the unexposed mothers.
More recent studies have focused on the question of reduced fertility in female
dental assistants exposed to nitrous oxide or to anesthetic gases in general. In an
American study (51) covering 7,000 female dental assistants exposed to nitrous
oxide or to combined anesthesia gases, telephone interviews were used to collect
information on exposure and time to pregnancy. An effort was made to differen-
tiate high from low exposure by asking whether there was exhaust ventilation.
No exposure levels are given. There was longer time to pregnancy in a group of
19 women described as highly exposed (no exhaust and more than 5 hours of
exposure per week). Similar data were presented by Ahlborg et al. (1) in a study
of midwives, in which 84% of 3,985 midwives responded to a questionnaire
on working conditions, exposures and pregnancy. There is no information on
exposure levels. The authors concluded that shift work has a negative effect
on fertility. Regarding effects of nitrous oxide, there were no noteworthy
observations except for reduced fertility in a small group of midwives who
assisted at more than 30 births per month. None of these studies gives expo-
sures other than those reported by the respondents in the form of time.
A large study of female dental assistants in the U.S., the same study material
and design as Rowland et al. 1992 (51), reports a more than doubled risk of
spontaneous abortion (RR = 2.6; 95% CI 1.3 – 5.0) for women occupationally
exposed to nitrous oxide for 3 or more hours per week. No data on exposure
levels are given: exposure is described only as 3 or more hours of work per
week in rooms without exhaust ventilation (52).
In a study by Axelsson et al. (4), based on the same material used by Ahlborg
et al. (1), it was found that the risk of spontaneous abortion was higher for shift
workers and night workers than for those working days. No correlation was found
between spontaneous abortions and exposure to nitrous oxide. A third publication
based on this material reports inhibition of prenatal growth and lower birth
weights (average 77 grams) in children whose mothers were exposed to nitrous
oxide during pregnancy (12). None of these studies gives exposure levels; the only
exposure information is that provided by the subjects in the form of estimates of
exposure time.
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In summary, there is a picture of elevated risk of spontaneous abortion
with occupational exposure to nitrous oxide, but it is difficult to assess. Early
studies show an elevated risk and more recent studies report little or no risk.
One explanation – aside from purely methodological sources of error – can be
that the studies reflect different exposure conditions: changes in work methods
introduced in the 1980s and 1990s have reduced exposure levels and thus also
reduced risks.
Dose-effect/dose-response relationships
There are few studies of occupationally exposed persons in which exposure was
restricted to nitrous oxide alone, and even fewer containing quantitative data on
exposure. Epidemiological studies have suggested that exposure to nitrous oxide
may be associated with toxic effects on reproduction (reduced fertility) (1, 51),
but dose-response relationships are poorly known.
Effects on reproduction of laboratory animals are summarized in Table 1. The
lowest exposure level at which statistically significant embryotoxic effects have
been observed in rats is 1000 ppm. One study reports elevated fetal mortality with
exposure to 100 ppm, but there are no adequate control group.
Acute effects on mental function with exposure to low concentrations of nitrous
oxide are summarized in Table 2. Disturbances of mental function were reported
in an experimental study with exposure to 50 and 500 ppm (91.5 and 915 mg/m3)
for four hours. The observations were not confirmed in other studies with expo-
sures up to 4000 ppm for 30 minutes, and the author himself later retracted his
conclusions.
Conclusions
There are no data from which to determine a critical effect of occupational
exposure to nitrous oxide.
Judging from animal experiments, the critical effect of exposure to nitrous
oxide is its toxic effect on reproduction. The lowest exposure level at which
statistically significant embryotoxic effects are seen in rats is 1000 ppm (1830
mg/m3). Occupational exposure has been shown to affect fertility, but in these
studies little is known about dose-response relationships.
When discussing an occupational exposure limit for nitrous oxide it has to be
taken into consideration that co-exposure to other anesthetic gases is common
and that joint effects may occur.
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Table 1. Embryotoxic/fetotoxic effects observed in rats experimentally exposed to low
concentrations of nitrous oxide (≤ 5000 ppm; 9150 mg/m3).
Exposure
(ppm)
Time Effects    Ref.
5000 24 hours/day, days
1–19 of gestation
Statistically significant increase in resorptions,
fewer pregnancies, higher incidences of skeletal
anomalies, inhibited fetal growth
64
5000 6 hours/day,
5 days/week, days
1–19 of gestation
Significant reduction in numbers of living fetuses 66
1000 24 hours/day, days
12–19 of gestation
Statistically significant reduction in pregnancies
and higher fetal mortality
25
1000 8 hours/day, days
10–13 of gestation
Statistically significant increase in fetal mortality 25
1000 24 hours/day, days
1–19 of gestation
Statistically significant reduction in number of
living fetuses, increased incidence of resorptions
and skeletal anomalies
65
500 24 hours/day, days
1–19 of gestation
No fetotoxic effect 65
250 24 hours/day, days
1-19 of gestation
No fetotoxic effect 65
100 8 hours/day, days
10–13 of gestation
Elevated fetal mortality
(adequate controls lacking)
25
Table 2. Acute effects on mental function observed with exposure to low concentrations of
nitrous oxide.
Exposure
(ppm)
Time
(minutes)
Dose
(ppm x min.)
Number of
subjects
Effects   Ref.
4000 30 120 000 10 No effect on mental function* 24
2000 30 60 000 10 No effect on mental function* 24
1000 30 30 000 10 No effect on mental function* 24
536 (average) – ** – ** 10
10 controls
No effect on mental function of
dentists during work*
5
500 240 120 000 30 Statistically significant changes
in mental function
14
210
(average)
35 7350 10 No effect on mental function of
dental assistants during work*
6
50 240 12 000 20 Statistically significant deterio-
ration of mental function
15
50 240 12 000 24 No effect on mental function* 63
* Applies only to the test systems used.
** No information given.
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Summary
Montelius J (ed). Scientific Basis for Swedish Occupational Standards. XXVII.
Arbete och Hälsa 2006:11:1-64. National Institute for Working Life, Stockholm.
Critical review and evaluation of those scientific data which are relevant as a background
for discussion of Swedish occupational exposure limits. This volume consists of the
consensus reports given by the Criteria Group at the Swedish National Institute for
Working Life from October, 2005 through June, 2006.
Key Words: Ammonia, n-Hexanal, Laughing gas, Nitrous oxide, Occupational exposure
limit (OEL), Penicillins, Risk assessment, Scientific basis, Toxicology.
Sammanfattning
Montelius J (ed). Vetenskapligt underlag för hygieniska gränsvärden. XXVII. Arbete och
Hälsa 2006:11:1-64. Arbetslivsinstitutet, Stockholm.
Sammanställningar baserade på kritisk genomgång och värdering av de vetenskapliga
fakta, vilka är relevanta som underlag för fastställande av hygieniskt gränsvärde.
Volymen omfattar de underlag som avgivits från Kriteriegruppen för hygieniska
gränsvärden under perioden oktober 2005 - juni 2006.
Nyckelord: Ammoniak, Dikväveoxid, n-Hexanal, Hygieniskt gränsvärde, Lustgas,
Penicilliner, Riskvärdering, Toxikologi, Vetenskapligt underlag.
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och Hälsa
2006:9.
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revised April 17, 1991 1992:6 (XII)
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revised December 1, 1987 1988:32 (IX)
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Methanol April 25, 1985 1985:32 (VI)
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Methylamine August 25, 1982 1983:36 (IV)
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Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
4,4´-methylene-bis-(2-chloroaniline) February 4 2004 2005:7 (XXV)
Methylene chloride February 29, 1980 1981:21 (I)
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Methylisocyanate (MIC) December 5 2001 2002:19 (XXIII)
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Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
MOCA February 4 2004 2005:7 (XXV)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
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Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nicotine June 2 2004 2005:7 (XXV)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
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Nitrotoluene February 20, 1991 1992:6 (XII)
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Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
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1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
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Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
Potassium cyanide February 7 2001 2001:20 (XXII)
Potassium dichromate May 24, 2000 2000:22 (XXI)
Potassium Fluoride September 15, 2004 2005:17 (XXVI)
Potassium hydroxide Marsh 15, 2000 2000:22 (XXI)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
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Propylene glycol June 6, 1984 1984:44 (V)
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Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Sodium cyanide February 7 2001 2001:20 (XXII)
Sodium Fluoride September 15, 2004 2005:17 (XXVI)
Sodium hydroxide August 24, 2000 2000:22 (XXI)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
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Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
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revised December 1, 1987 1988:32 (IX)
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Tetrahydrofuran October 31, 1989 1991:8 (XI)
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